Non-invasive ventilation as an airway clearance adjunct in exacerbations on non-CF bronchiectasis by Bradley, Judy et al.
Non-invasive ventilation as an airway clearance adjunct in
exacerbations on non-CF bronchiectasis
Bradley, J., Moran, F., Piper, A. J., Hewitt, O., McCrum-Gardner, E., King, M., & Elborn, J. (2017). Non-invasive
ventilation as an airway clearance adjunct in exacerbations on non-CF bronchiectasis. Cochrane database of
systematic reviews (Online), (2), [46]. DOI: 10.1002/14651858.CD002769
Published in:
Cochrane database of systematic reviews (Online)
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This work is made available online in accordance with
the publisher’s policies. Please refer to any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:06. Aug. 2018
Cochrane Database of Systematic Reviews
Non-invasive ventilation for cystic fibrosis (Review)
Moran F, Bradley JM, Piper AJ
Moran F, Bradley JM, Piper AJ.
Non-invasive ventilation for cystic fibrosis.
Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No.: CD002769.
DOI: 10.1002/14651858.CD002769.pub5.
www.cochranelibrary.com
Non-invasive ventilation for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
21REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 1 CFQ scores. 44
Analysis 1.2. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 2 Fatigue. . 44
Analysis 1.3. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 3 FEV1 (L). 45
Analysis 1.4. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 4 FEV1 (%
predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Analysis 1.5. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 5 FVC (L). . 47
Analysis 1.6. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 6 FVC (%
predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Analysis 1.7. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 7 FEF25-75 (L). 49
Analysis 1.8. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 8 FEF25-75 (%
predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Analysis 1.9. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 9 Respiratory
muscle strength PImax (cmH20). . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Analysis 1.10. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 10 Respiratory
muscle strength PEmax (cmH20). . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Analysis 1.11. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 11 Airway
resistance % predicted. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Analysis 1.12. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 12 LCI. . 52
Analysis 1.13. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 13 Oxygen
saturation during airway clearance (%). . . . . . . . . . . . . . . . . . . . . . . . . . 52
Analysis 1.14. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 14 Oxygen
saturation during airway clearance (change in SpO2 % during treatment). . . . . . . . . . . . . . 53
Analysis 1.15. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 15 Oxygen
saturation after airway clearance (SpO2). . . . . . . . . . . . . . . . . . . . . . . . . 53
Analysis 1.16. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 16 PaCO2. 54
Analysis 1.17. Comparison 1NIV versus noNIV during chest physiotherapy (any technique), Outcome 17 Breathlessness. 54
Analysis 1.18. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 18 Sputum wet
weight (g). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
Analysis 1.19. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 19 Sputum dry
weight (g). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Analysis 1.20. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 20 Sputum
volume per day (VAS score). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Analysis 1.21. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 21 Pseudomonas
density (log CFU/g). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Analysis 1.22. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 22 Exercise
capacity: 25 level modified shuttle test (m). . . . . . . . . . . . . . . . . . . . . . . . . 57
Analysis 1.23. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 23 Energy (VAS
score). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
iNon-invasive ventilation for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.24. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 24 6MWT. 58
Analysis 1.25. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 25 Length of
hospital stay (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Analysis 1.26. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 26 Time to next
admission (days). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Analysis 2.1. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 1 CFQoL chest symptom score. 60
Analysis 2.2. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 2 CFQoL transitional dyspnoea
index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Analysis 2.3. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 3 Symptoms of sleep-disordered
breathing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Analysis 2.4. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 4 Lung function during sleep. 62
Analysis 2.5. Comparison 2NIV in overnight ventilation compared to oxygen, Outcome 5 Respiratory rate (breaths/min). 63
Analysis 2.6. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 6 Lung function while awake. 63
Analysis 2.7. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 7 Arterial blood gases: pH. 64
Analysis 2.8. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 8 Arterial blood gases: PaO2
(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Analysis 2.9. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 9 Arterial blood gases: PaCO2
(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Analysis 2.10. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 10 Arterial blood gases: HCO3
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Analysis 2.11. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 11 Arterial blood gases: SaO2
(%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 2.12. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 12 Exercise performance
(MSWT) (metres). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 2.13. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 13 Total sleep time (min). 67
Analysis 2.14. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 14 REM sleep architecture. 68
Analysis 2.15. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 15 Sleep latency (min). . 69
Analysis 2.16. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 16 Nocturnal oxygen saturation
(%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
Analysis 2.17. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 17 Nocturnal oxygen saturation
(%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Analysis 2.18. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 18 Nocturnal TcCO2
(mmHg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Analysis 2.19. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 19 Nocturnal TcCO2
(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Analysis 2.20. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 20 Nocturnal TcCO2 TST
(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Analysis 2.21. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 21 Hypopneas. . . . . 74
Analysis 2.22. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 22 Mean heart rate
(beats/min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Analysis 2.23. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 23 Respiratory rate. . . 75
Analysis 3.1. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 1 CF QoL chest symptom
score. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
Analysis 3.2. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 2 CF QoL traditional dyspnoea
index score. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Analysis 3.3. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 3 Symptoms of sleep-disordered
breathing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Analysis 3.4. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 4 Lung function during sleep. 77
Analysis 3.5. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 5 Respiratory rate(breaths/min)
during sleep. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
Analysis 3.6. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 6 Mean Respiratory Rate. 78
Analysis 3.7. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 7 Mean Heart Rate
(beats/min). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
iiNon-invasive ventilation for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.8. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 8 Lung function while awake. 79
Analysis 3.9. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 9 Arterial blood gases: pH. 80
Analysis 3.10. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 10 Arterial blood gases: PaO2
(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Analysis 3.11. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 11 Arterial blood gases: PaCO2
(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Analysis 3.12. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 12 Arterial blood gases: HCO3
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Analysis 3.13. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 13 Arterial blood gases: SaO2
(%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Analysis 3.14. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 14 Exercise performance
(metres). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Analysis 3.15. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 15 Total sleep time (min). 83
Analysis 3.16. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 16 REM sleep architecture. 83
Analysis 3.17. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 17 Sleep latency. . . . 84
Analysis 3.18. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 18 Nocturnal oxygen saturation
(%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Analysis 3.19. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 19 Nocturnal oxygen saturation
(%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Analysis 3.20. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 20 Nocturnal TcCO2
(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Analysis 3.21. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 21 Nocturnal
TcCO2(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Analysis 3.22. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 22 Nocturnal TcCO2 TST
(mmHg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Analysis 3.23. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 23 Hypopneas. . . . 89
Analysis 4.1. Comparison 4 NIV versus no NIV during exercise testing, Outcome 1 6 minute walk test. . . . . . 89
89ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
92WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
93HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
94CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
94DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
95SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
95DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
95INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiiNon-invasive ventilation for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Non-invasive ventilation for cystic fibrosis
Fidelma Moran1, Judy M Bradley2, Amanda J Piper3
1Institute ofNursing andHealth Research and School ofHealth Sciences, UlsterUniversity,Newtownabbey,UK. 2TheWellcomeTrust-
Wolfson Northern Ireland Clinical Research Facility U Floor, Queen’s University Belfast, Belfast, UK. 3Department of Respiratory and
Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia
Contact address: Fidelma Moran, Institute of Nursing and Health Research and School of Health Sciences, Ulster University, Shore
Road, Newtownabbey, Northern Ireland, BT37 0QB, UK. f.moran@ulster.ac.uk.
Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 2, 2017.
Citation: Moran F, Bradley JM, Piper AJ. Non-invasive ventilation for cystic fibrosis. Cochrane Database of Systematic Reviews 2017,
Issue 2. Art. No.: CD002769. DOI: 10.1002/14651858.CD002769.pub5.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Non-invasive ventilationmay be ameans to temporarily reverse or slow the progression of respiratory failure in cystic fibrosis by providing
ventilatory support and avoiding tracheal intubation. Using non-invasive ventilation, in the appropriate situation or individuals, can
improve lung mechanics through increasing airflow and gas exchange and decreasing the work of breathing. Non-invasive ventilation
thus acts as an external respiratory muscle. This is an update of a previously published review.
Objectives
To compare the effect of non-invasive ventilation versus no non-invasive ventilation in people with cystic fibrosis for airway clearance,
during sleep and during exercise.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from compre-
hensive electronic database searches, handsearching relevant journals and abstract books of conference proceedings. We searched the
reference lists of each trial for additional publications possibly containing other trials.
Most recent search: 08 August 2016.
Selection criteria
Randomised controlled trials comparing a form of pressure preset or volume preset non-invasive ventilation to no non-invasive
ventilation used for airway clearance or during sleep or exercise in people with acute or chronic respiratory failure in cystic fibrosis.
Data collection and analysis
Three reviewers independently assessed trials for inclusion criteria and methodological quality, and extracted data.
Main results
Ten trials met the inclusion criteria with a total of 191 participants. Seven trials evaluated single treatment sessions, one evaluated a
two-week intervention, one evaluated a six-week intervention and one a three-month intervention. It is only possible to blind trials of
airway clearance and overnight ventilatory support to the outcome assessors. In most of the trials we judged there was an unclear risk
of bias with regards to blinding due to inadequate descriptions. The six-week trial was the only one judged to have a low risk of bias for
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all other domains. One single intervention trial had a low risk of bias for the randomisation procedure with the remaining trials judged
to have an unclear risk of bias. Most trials had a low risk of bias with regard to incomplete outcome data and selective reporting.
Six trials (151 participants) evaluated non-invasive ventilation for airway clearance compared with an alternative chest physiotherapy
method such as the active cycle of breathing techniques or positive expiratory pressure. Three trials used nasal masks, one used a nasal
mask or mouthpiece and one trial used a face mask and in one trial it is unclear. Three of the trials reported on one of the review’s
primary outcome measures (quality of life). Results for the reviews secondary outcomes showed that airway clearance may be easier
with non-invasive ventilation and people with cystic fibrosis may prefer it. We were unable to find any evidence that non-invasive
ventilation increases sputum expectoration, but it did improve some lung function parameters.
Three trials (27 participants) evaluated non-invasive ventilation for overnight ventilatory support compared to oxygen or room air
using nasal masks (two trials) and nasal masks or full face masks (one trial). Trials reported on two of the review’s primary outcomes
(quality of life and symptoms of sleep-disordered breathing). Results for the reviews secondary outcome measures showed that they
measured lung function, gas exchange, adherence to treatment and preference, and nocturnal transcutaneous carbon dioxide. Due to
the small numbers of participants and statistical issues, there were discrepancies in the results between the RevMan and the original
trial analyses. No clear differences were found between non-invasive ventilation compared with oxygen or room air except for exercise
performance, which significantly improved with non-invasive ventilation compared to room air over six weeks.
One trial (13 participants) evaluated non-invasive ventilation on exercise capacity (interface used was unclear) and did not reported
on any of the review’s primary outcomes. The trial found no clear differences between non-invasive ventilation compared to no non-
invasive ventilation for any of our outcomes.
Three trials reported on adverse effects. One trial, evaluating non-invasive ventilation for airway clearance, reported that a participant
withdrew at the start of the trial due to pain on respiratory muscle testing. One trial evaluating non-invasive ventilation for overnight
support reported that one participant could not tolerate an increase in inspiratory positive airway pressure. A second trial evaluating
non-invasive ventilation in this setting reported that one participant did not tolerate the non-invasive ventilation mask, one participant
developed a pneumothorax when breathing room air and two participants experienced aerophagia which resolved when inspiratory
positive airway pressure was decreased.
Authors’ conclusions
Non-invasive ventilation may be a useful adjunct to other airway clearance techniques, particularly in people with cystic fibrosis who
have difficulty expectorating sputum. Non-invasive ventilation, used in addition to oxygen, may improve gas exchange during sleep to
a greater extent than oxygen therapy alone in moderate to severe disease. The effect of NIV on exercise is unclear. These benefits of
non-invasive ventilation have largely been demonstrated in single treatment sessions with small numbers of participants. The impact of
this therapy on pulmonary exacerbations and disease progression remain unclear. There is a need for long-term randomised controlled
trials which are adequately powered to determine the clinical effects of non-invasive ventilation in cystic fibrosis airway clearance and
exercise.
P L A I N L A N G U A G E S U M M A R Y
Amachine pushes air into the lungs helping people with cystic fibrosis breathe, clear mucus, reduce respiratory failure, improve
exercise tolerance
Review question
We reviewed the evidence that mechanically pushing air into the lungs through a mask helps clear mucus, improves breathing overnight,
reduces respiratory failure and improves exercise tolerance.
Background
As cystic fibrosis worsens, breathing becomes difficult, indicating the start of respiratory failure (too much carbon dioxide and not
enough oxygen in the blood). As respiratory failure progresses, people may become breathless and have problems clearing mucus.
Respiratory failure eventually results in death.
Non-invasive ventilation administers room air or oxygen through a mask and has been used to help people with more severe cystic
fibrosis to clear their airways of mucus and improve breathing during sleep; it may also help with exercise. It is not certain exactly how
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this works, but it might reduce fatigue in the respiratory muscles, stop the airways from closing during prolonged exhalation and reduce
the effort needed to maintain ventilation and oxygen levels. Treatment has been recommended when breathing muscles are weak, when
a person has difficulty clearing mucus using other airway clearance techniques or when there are high levels of carbon dioxide in the
blood during sleep or during exercise.
This is an update of a previously published review.
Search date
Evidence is current to 08 August 2016.
Study characteristics
This review includes 10 trials (191 people with cystic fibrosis) - seven single-treatment sessions and a two-week trial, a six-week trial and
a three-month trial. Six single-treatment trials, the two-week trial and the three-month trial compared non-invasive ventilation with
other airway clearance techniques. Two single-treatment trials and the six-week trial looked at non-invasive ventilation for overnight
breathing support compared to oxygen or normal room air. One single-treatment trial compared non-invasive ventilation with no
additional treatment during an exercise test.
Key results
Single-treatment trials of non-invasive ventilation for airway clearance showed that this may be easier with non-invasive ventilation
and people with cystic fibrosis may prefer it to other methods. We could not find evidence that non-invasive ventilation increased the
amount of mucus coughed up, but it did improve some measures of lung function, at least in the short term. The two-week trial did
not demonstrate clear benefits between groups. The original three-month trial report stated an improvement in lung clearance index.
One person in one of these trials reported pain on respiratory muscle testing.
The three trials comparing overnight support from non-invasive ventilation measured lung function, quality of life and carbon dioxide
levels; they showed it is effective, safe and acceptable. We found no clear differences between non-invasive ventilation and oxygen or
room air, except for exercise performance which improved with non-invasive ventilation compared to room air after six weeks. Two
trials reported side effects. In the first trial, one person found the mask uncomfortable. In the second trial, one person in the room air
group had collapsed lungs and two people could not tolerate increased pressure when breathing in.
The trial comparing the effects of non-invasive ventilation to no treatment on exercise capacity found no clear differences between
groups.
Non-invasive ventilation may help alongside other airway clearance techniques, particularly when people with cystic fibrosis have
difficulty coughing up mucus and during sleep. Long-term trials are needed with enough people to show the clinical effects of non-
invasive ventilation on airway clearance, during sleep and exercise training in severe disease.
Quality of the evidence
The benefits of non-invasive ventilation have largely been demonstrated in single-treatment sessions with only small numbers of people.
There is limited evidence of some longer-term improvement in lung function in one trial. Our results from the trials of overnight
breathing support differed from those in the original analyses, this is likely due to the small numbers of participants and some statistical
issues.We judged only the six-week trial to be free from any bias. In the remaining trials, we thought there were low or unclear chances of
the results being affected because data were either reported only partially or not at all. We were not sure if the way in which participants
were put into the different treatment groups would affect the results of the trials.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common life-limiting autosomal
recessively genetically inherited disease in Caucasian populations,
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with a carrier rate of 1 in 25 and an incidence of 1 in 2,500 live
births (UKCFTrust 2011). Although this is amultisystemdisease,
the primary cause of death in CF is respiratory failure. Respiratory
failure can be defined as the inability of the respiratory pump and
lungs to maintain adequate gas exchange and is characterised by
abnormalities of arterial blood gas tensions (Davidson 2016).
In CF, severe airway obstruction and inflammatory bronchiectatic
processes results in sputum retention, an increase in breathlessness,
hyperinflation, ventilation perfusion mismatch, a decrease in res-
piratory muscle strength, and an inability to maintain arterial oxy-
genation within normal limits. When this occurs, reflex hypoxic
vasoconstriction results in elevation of the blood pressure within
the pulmonary circulation, right ventricular strain and, eventually,
cor pulmonale.
Description of the intervention
With non-invasive mask ventilation, positive pressure ventilatory
assistance can be delivered in the form of inspiratory pressure sup-
port (pressure pre-set) systems which deliver a variable volume ac-
cording to a pre-set inspiratory pressure. Alternatively, a set tidal
volume (volume pre-set) systemmay be used which delivers a fixed
tidal volume irrespective of the airway pressure required to gen-
erate this volume. The earliest trials of non-invasive ventilation
(NIV) employed volume pre-set equipment. However, later trials
have used pressure pre-set devices, primarily due to simplicity and
the comfort of the individual. The NIV machines entrain room
air and additional oxygen may be entrained into the ventilatory
tubing, or directly into the mask.
How the intervention might work
Non-invasive ventilation may be beneficial in acute respiratory
failure in CF and could have a role to play in the management of
chronic respiratory failure by acting as a bridge to transplantation
as it may reverse or stabilise hypercapnia and hypoxaemia by im-
proving alveolar ventilation, reducing respiratory muscle fatigue,
or both (Hodson 1991; Piper 1992; Yankaskas 1999). The exact
mechanisms by which NIV induces these changes may be differ-
ent in acute and chronic disease and consequently different out-
come measures may be necessary to reflect adequately the efficacy
of NIV in acute and chronic respiratory failure in CF.
Clinically, NIV has been used as an adjunct to airway clearance
techniques in people with CF and moderate to severe disease. The
exact mechanisms by which NIV may assist airway clearance are
unclear, but it is postulated that decreased respiratory muscle fa-
tigue and prevention of airway closure during prolonged expira-
tions may ultimately lead to an increase in effective alveolar ven-
tilation, better compliance with airway clearance and increased
sputum clearance (Holland 2003). Furthermore, recent guidelines
state that NIV should be used for airway clearance in people with
CF if there is respiratory muscle weakness or fatigue; where de-
saturation is present during airway clearance techniques; or when
an individual has difficulty clearing secretions with other airway
clearance techniques (Bott 2009).
In people with CF, NIV has also been used during sleep when
decreases in respiratory neuromuscular output exaggerate these
changes and lead to nocturnal hypoventilation before daytime res-
piratory failure becomes evident (Ballard 1996). While the ad-
dition of nocturnal oxygen improves hypoxaemia and may have
favourable effects on cor pulmonale, it has not been shown to af-
fect the progression of disease in CF (Zinman 1989). There is also
some evidence that the use of oxygen therapy may be at the ex-
pense of worsening hypercapnia (Gozal 1997; Milross 2001). The
use of NIV has been proposed as a means to temporarily reverse
this process by assisting nocturnal ventilation, thereby slowing the
progression of respiratory failure. The aim of NIV is to reduce
hypoventilation and improve gas exchange by increasing minute
ventilation and reducing the work of breathing without the asso-
ciated complication of endotracheal intubation.
Finally, NIV has also been used during exercise in people with
CF. There is a reasoned argument for using NIV during exercise
to decrease dyspnoea and increase oxygenation resulting in an
improvement in exercise tolerance; however there is no objective
evidence to support this at present (Bott 2009).
Why it is important to do this review
It has been proposed that NIVmay have a role in airway clearance,
during sleep and during exercise in people with CF. In order to
establish an evidence base for the use of NIV, this review will aim
to determine the effect of NIV in the management of acute and
chronic respiratory failure in CF.
This is an update of previous versions of this review (Moran 2003;
Moran 2007; Moran 2011; Moran 2013).
O B J E C T I V E S
The aim of this review is to compare the effect of pressure pre-set
or volume pre-set NIV (that aims to increase minute ventilation)
to no NIV in people with CF for airway clearance, during sleep
and during exercise.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Randomised controlled clinical trials.
Types of participants
People with CF, of any age, diagnosed on the basis of clinical
criteria and sweat testing or genotype analysis with any type of
acute and chronic respiratory failure.
Types of interventions
Any type of prescribed pressure preset or volume preset method of
NIV will be considered and compared to any other management
strategy for acute and chronic respiratory failure.
Types of outcome measures
Primary outcomes
1. Mortality
2. Quality of life (QoL)
3. Symptoms of sleep-disordered breathing
Secondary outcomes
1. Lung function
2. Gas exchange
3. Respiratory symptom scores and sputum production
4. Exercise tolerance
5. Impact on health resources
6. Nocturnal polysomnography
7. Nutrition and weight
8. Right-sided cardiac function
9. Cost
10. Adherence to treatment and preference
11. Adverse events
Search methods for identification of studies
Electronic searches
Relevant trials were identified from the Group’s Cystic Fibrosis
Trials Register using the terms: ventilatory support AND non-
invasive.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and theJournal of Cystic Fibrosis. Unpublished work is identified
by searching through the abstract books of three major cystic fi-
brosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and theNorth American
Cystic Fibrosis Conference. For full details of all searching activ-
ities for the register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group’s website.
Date of the most recent search of the Group’s CF Trials Register:
08 August 2016.
Searching other resources
The bibliographic references of all retrieved trials were assessed for
additional reports of trials.
Data collection and analysis
Selection of studies
Three authors (JB, AP, FM) independently selected the trials to
be included in the review using a pro forma to capture the main
inclusion criteria listed above. Disagreement did not arise on the
suitability of a trial for inclusion in the review. However if this
occurs for future updates of this review, the authors plan to reach
a consensus by discussion.
Data extraction and management
Two authors independently extracted data using standard data
acquisition forms: FM and JB extracted data from seven trials
(Dwyer 2015; Gozal 1997; Kofler 1998; Fauroux 1999; Milross
2001; Holland 2003; Young 2008); FM and AP extracted data
from three trials (Placidi 2006; Lima 2014; Rodriguez Hortal
2016).Disagreement did not arise on the quality of a trial included
in the review. However, if this occurs for future updates of this
review, the authors plan to reach a consensus by discussion.
In a post hoc change short-term trials were defined as those with a
duration less than three months. The authors decided to analyse
single-night interventions separately from other short-term trials
as they did not feel it appropriate to combine them with other
longer trials. They planned to group outcome data from longer-
term trials into those measured at three, six, twelve months and
annually thereafter. In future, the authors will also consider exam-
ining any outcome data recorded at other time periods.
Assessment of risk of bias in included studies
In order to assess the risk of bias in the included trials (yes, no
or unclear), the authors (as identified above) then assessed the
methodological quality of each included trial based on a method
described by Jüni (Jüni 2001). In particular, the authors examined
details of the method of randomisation used, the method used to
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conceal allocation, whether the trial was blinded, whether asses-
sors were independent or involved in the delivery of the interven-
tions and if the number of participants lost to follow up or sub-
sequently excluded from the trial were recorded. The authors as-
sessed whether the primary investigators had made any statement
regarding intention-to-treat analyses.
Measures of treatment effect
The authors combined data from all trials using the RevMan soft-
ware (RevMan 2014). For continuous variables they calculated the
mean difference (MD) and their 95% confidence intervals (CI).
For count data from cross-over trials, they used Poisson regression
to analyse the data and they have presented the results as a relative
rate. The authors carried out these analyses in Stata (Stata 2001)
and present the results in RevMan (RevMan 2014).
There were no binary data in any of the trials included in this
review. If the authors include binary data in future updates of this
review, they will aim to calculate a pooled estimate of the treat-
ment effect for each outcome across trials (the odds of an outcome
among treatment allocated participants to the corresponding odds
among controls).
Unit of analysis issues
Eight of the 10 trials included in this review were cross-over in
design. When conducting a meta-analysis combining results from
cross-over trials the authors would have liked to have used the
methods recommended by Elbourne (Elbourne 2002) and also by
Curtin (Curtin 2002). However, due to restrictions on the data
that were available, the authors treated the cross-over trials as if
they were parallel trials, except for the Milross trial where further
individual participant data was provided by the trial authors (
Milross 2001). Elbourne states that this approach will produce
conservative results, as it does not take into account within-patient
correlation (Elbourne 2002). Also each participant will appear in
both the treatment and control group, so the two groups will not
be independent. This may explain discrepancies found between
original trial analyses and data presented in the review (Data and
analyses). Where the authors have found discrepancies, both data
from the original analyses and the statistical analysis for the review
are detailed in the results. Another possible reason for discrepancies
is that the methods used to analyse data were not always identical
between the original trial report and the review. The authors note
where this is the case in the text of the Effects of interventions
section.
Although three trials evaluated NIV as a method of overnight
ventilation involving overnight sleep trials in groups of participants
which were similar in terms of age, lung function, body mass index
and resting arterial blood gases, the authors did not pool the results
as the control group interventions were sufficiently different in
the three trials (Gozal 1997; Milross 2001; Young 2008) and also
one of these was six weeks in duration as compared to a single
intervention (Young 2008).
Dealing with missing data
The review authors contacted several of the original Investigators
for further information (Fauroux 1999; Gozal 1997; Holland
2003; Kofler 1998; Milross 2001; Placidi 2006). Holland and
Milross provided further data for analysis (Holland 2003; Milross
2001) and Young clarified the study design (Young 2008). The
review authors will contact authors of potentially eligible studies
(currently reported in abstract form and only with very limited
data) for future updates.
Assessment of heterogeneity
The review authors tested for heterogeneity between trial results
using the I² statistic (Higgins 2003). This measure describes the
percentage of total variation across trials that are due to hetero-
geneity rather than chance (Higgins 2003). The values of I² lie
between 0% and 100%, and a simplified categorization of het-
erogeneity that we used is of low (I² value of 25%), moderate (I²
value of 50%), and high (I² value of 75%) (Higgins 2003).
Assessment of reporting biases
The review authors identified potential reporting bias by compar-
ing the ’Methods’ section with the ’Results’ section in the pub-
lished papers to see if all stated outcome measures are reported in
the results of the full publication. One trial is published in abstract
format only, so in this case the comparison was not possible (Kofler
1998). In future updates, if the review authors include a sufficient
number of trials, they plan to investigate potential publication bias
using a funnel plot.
Data synthesis
The review authors have analysed the data using a fixed-effect
analysis. If in future, they establish heterogeneity between included
trials, they will analyse the data using a random-effects analysis.
Subgroup analysis and investigation of heterogeneity
Although the review authors planned to do so, at present it is not
possible to investigate heterogeneity by age or disease severity or
mode of ventilation. Some trials include adults and children with
mixed disease severities, with insufficient data in each subsection
for analysis. There is also insufficient data to facilitate subgroup
analysis by mode of ventilation.
6Non-invasive ventilation for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sensitivity analysis
The review authors also planned to further investigate any hetero-
geneity by performing a sensitivity analysis based on the method-
ological quality of the included trials and will do so once there are
sufficient trials to allow this.
A sensitivity analysis was performed entering the Placidi data sep-
arately so that participants were not counted twice i.e. either chest
physiotherapy including directed cough or chest physiotherapy
including PEP and both data were reported.
R E S U L T S
Description of studies
A full list of abbreviations can be found in the additional tables
section (Table 1).
Results of the search
The searches identified 24 trials; 10 of these fulfilled the inclu-
sion criteria and included a total of 191 participants (Dwyer
2015; Fauroux 1999; Gozal 1997; Holland 2003; Kofler 1998;
Lima 2014; Milross 2001; Placidi 2006; Rodriguez Hortal 2016;
Young 2008). A total of 13 trials were excluded (Elkins 2004; Falk
2006; Fauroux 2000a; Fauroux 2000b; Fauroux 2001; Fauroux
2004; Greenough 2004;Parreira 2008; Piper 1992; Regnis 1994;
Serra 2000; Serra 2002; Riethmueller 2006). One trial is listed as
’Awaiting classification’ until further details are published (Petrone
2009).
Included studies
Data from one of the included trials are reported in abstract form
only (Kofler 1998). In one of the trials, NIVwas compared tomore
than one intervention within the same trial (Placidi 2006). For
this trial, independent analyses for NIV versus directed coughing
and NIV versus positive expiratory pressure (PEP) are reported
(Placidi 2006). Therefore, 10 trials contributing 11 randomised
data sets have been included in this review.
Trial design
Eight of the included trials were cross-over in design (Fauroux
1999; Gozal 1997; Holland 2003; Kofler 1998; Lima 2014;
Milross 2001; Placidi 2006; Young 2008) and two employed a
parallel design (Dwyer 2015; Rodriguez Hortal 2016). Due to the
way data have been reported in the original papers, we have chosen
to ignore the cross-over design and treat the data from these trials
as if it originated from parallel trials, except for theMilross trial for
which individual patient data were obtained (see Data collection
and analysis and the table Characteristics of included studies).
The trials in this review were all short- to medium-term trials.
Six trials compared a single session of NIV to a single session of
another type of intervention (Fauroux 1999; Gozal 1997; Holland
2003; Kofler 1998;Milross 2001; Placidi 2006) and one compared
a single session of NIV to no treatment (Lima 2014); one trial
compared NIV to another type of airway clearance during a two-
week exacerbation period (Dwyer 2015); one trial reported a six-
week intervention of nocturnal NIV compared to oxygen and air
(Young 2008); and one compared NIV to another type of airway
clearance over a three-month period (Rodriguez Hortal 2016).
Inclusion criteria were stated in eight trials (Dwyer 2015; Gozal
1997; Holland 2003; Lima 2014; Milross 2001; Placidi 2006;
Young 2008; Rodriguez Hortal 2016) and exclusion criteria were
explicitly stated in six trials (Dwyer 2015; Holland 2003; Lima
2014; Placidi 2006; Young 2008; Rodriguez Hortal 2016).
In eight trials the participants were studied in a hospital setting
(Dwyer 2015; Fauroux 1999; Gozal 1997; Holland 2003; Kofler
1998; Lima 2014; Milross 2001; Placidi 2006) and participants
were at home in two trials (Young 2008;Rodriguez Hortal 2016 ).
Participants
Two trials included children only (Fauroux 1999; Lima 2014);
two trials included both adults and children (Gozal 1997; Kofler
1998); and six trials included adults only (Dwyer 2015; Holland
2003;Milross 2001; Placidi 2006; Young 2008; Rodriguez Hortal
2016). Of the 191 participants, 114 were male (59.7%) and 72
(40.3%) were female. The number of participants in the trials
ranged from 6( Gozal 1997) to 40( Dwyer 2015).
In six of the trials it is stated that participants were stable at the time
of the trial (Fauroux 1999; Gozal 1997; Lima 2014;Milross 2001;
Young 2008; Rodriguez Hortal 2016); in three trials participants
had an acute exacerbation (Dwyer 2015; Holland 2003; Placidi
2006); and in one trial disease status is not clear (Kofler 1998).
The trials included people with a range of disease severity. One
trial recruited participants with mild (not defined) disease (Kofler
1998), while five trials recruited participants with moderate to se-
vere (defined) disease (Dwyer 2015; Holland 2003; Milross 2001;
Young 2008; Rodriguez Hortal 2016). Two trials had participants
in all disease categories (Fauroux 1999; Lima 2014). Participants
in the remaining two trials had severe disease (Gozal 1997; Placidi
2006). For further details, please see the table (Characteristics of
included studies).
Interventions
All machines used were positive pressure ventilators with a capac-
ity for bilevel pressure ventilatory support (see Characteristics of
included studies).
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NIV as a method of airway clearance
Six trials, with a total of 151 participants, evaluated NIV as a
method of airway clearance (Dwyer 2015; Fauroux 1999; Holland
2003; Kofler 1998; Placidi 2006; Rodriguez Hortal 2016). Four
trials compared a single treatment session of NIV to another
airway clearance technique: PEP (Kofler 1998; Placidi 2006) or
chest physiotherapy (Fauroux 1999;Holland 2003; Placidi 2006).
Three trials used a nasal mask (Fauroux 1999; Holland 2003;
Placidi 2006), one trial used nasal mask or mouthpiece (Dwyer
2015), one trial used a face mask (Rodriguez Hortal 2016) and in
one trial it is unclear how NIV was administered (Kofler 1998).
One trial compared NIV to PEP over three months (Rodriguez
Hortal 2016). Only one trial compared NIV to more than one
active intervention (Placidi 2006). One trial compared NIV with
or without an additional airway clearance technique to no NIV
i.e. another type of airway clearance during a two-week course of
treatment for an acute exacerbation (Dwyer 2015).
NIV in overnight ventilation
Three trials, with a total of 27 participants, evaluated NIV as
a method of overnight ventilation (Gozal 1997; Milross 2001;
Young 2008). Two trials were single-night trials (Gozal 1997;
Milross 2001) and the remaining trial lasted six weeks (Young
2008); the results are later presented separately. Two of these stud-
ies used a nasal mask (Gozal 1997; Milross 2001), one used either
a nasal mask or a full face mask (Young 2008). In one single-night
trial, participants received room air on the first trial night (Gozal
1997). If they exhibited significant hypoxaemia or hypercapnia or
both on the room air night, the results were compared to a single
overnight session of NIV and oxygen and to a single overnight
session of oxygen (Gozal 1997). In the second single-night trial an
overnight session of NIV (with or without oxygen) was compared
to an overnight session of low level continuous positive airway
pressure (CPAP) and oxygen and a single overnight session of low
levelCPAP and room air (Milross 2001). In a domiciliary six-week
trial, CF participants with daytime hypercapnia received six weeks
of room air or oxygen or NIV (Young 2008).
NIV and exercise
One single-treatment trial, with a total of 13 participants, evalu-
ated NIV compared to no NIV during exercise (Lima 2014). The
interface used is unclear.
Outcomes
Three of the six trials assessingNIV as amethodof airway clearance
reported on one primary outcome measure (QoL) (Dwyer 2015;
Fauroux 1999; Placidi 2006). The other outcome measures for
the trials in this comparison focused on lung function, respiratory
muscle strength, gas exchange, sputum weight or volume, ease of
expectoration, breathlessness, fatigue, modified shuttle walk test,
bacterial density of Pseudomonas aeruginosa, length of hospital stay
and time to next admission, as well as participant and physio-
therapist preference (Dwyer 2015; Fauroux 1999; Holland 2003;
Kofler 1998; Placidi 2006; Rodriguez Hortal 2016).
The outcomes comparing NIV as a method of overnight ventila-
tion during sleep focused on CF-specific QoL questionnaires (a
primary outcome for this review), daytime sleepiness scores, lung
function, gas exchange, nocturnal polysomnography, modified
shuttle walk test, adherence to treatment and preference (Gozal
1997; Milross 2001; Young 2008).
The trial comparing NIV to no treatment during exercise did
not report on any of the review’s primary outcomes and reported
distance walked (Lima 2014).
No adverse effects of treatment were described in any trial. Five
trials did not make any comments on negative effects (Fauroux
1999; Gozal 1997; Lima 2014; Placidi 2006; Rodriguez Hortal
2016). Two trials reported that there were no untoward effects in
any participant (Dwyer 2015; Kofler 1998). Three trials provided
information about negative effects (Holland 2003; Milross 2001;
Young 2008).
Excluded studies
Two trials were excluded because they were not randomised con-
trolled trials (Piper 1992; Regnis 1994) and seven were excluded
as they did not compare NIV with other management for acute or
chronic respiratory failure (Elkins 2004; Fauroux 2000a; Fauroux
2000b; Fauroux 2001; Fauroux 2004; Serra 2000; Serra 2002).
Four trials were excluded as they did not include NIV (Falk 2006;
Greenough 2004; Parreira 2008; Riethmueller 2006).
Studies awaiting classification
One study is in abstract form and has limited data regarding re-
cruitment and randomisation and will be assessed when published
as a full trial (Petrone 2009).
Risk of bias in included studies
The quality of all the included trials was originally assessed based
on the criteria described by Jüni (Jüni 2001). However, one of the
included trials has only been published in abstract form (Kofler
1998) and there is limited information in the abstract to assess
quality using the quality assessment criteria we have employed.
We have since used the Cochrane risk of bias tool to assess the risks
of bias associated with the included studies and these are reported
below
Allocation
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Generation of randomisation sequence
The methods for the randomisation of treatment order were re-
ported in four trials, therefore there is a low risk of bias for these tri-
als (Dwyer 2015; Lima 2014; Placidi 2006; Young 2008). Dwyer
and Lima both used computer-generated block randomisation
(Dwyer 2015; Lima 2014) and both Young and Placidi employed
the Latin square design to randomise treatment order (Placidi
2006; Young 2008). We judged the remaining six trials to have
an unclear risk of bias due to a lack of description of the meth-
ods, despite being described as randomised trials (Fauroux 1999;
Gozal 1997;Holland 2003; Kofler 1998;Milross 2001; Rodriguez
Hortal 2016).
Concealment of allocation
Three trials were judged to have a low risk of bias for allocation
concealment as they all stated that opaque envelopes were used
to contain the order of randomisation (Dwyer 2015; Rodriguez
Hortal 2016; Young 2008). Additionally, Dwyer reported that
the sealed sequentially numbered opaque envelopes were opened
after consent was signed (Dwyer 2015); and in the Young trial,
the sequentially numbered envelopes were sealed by a person not
involved in the trial and opened as each participant was enrolled
(Young 2008). There were no details of allocation concealment
given in seven trials, therefore these have an unclear risk of bias
(Fauroux 1999; Gozal 1997; Holland 2003; Kofler 1998; Lima
2014; Milross 2001; Placidi 2006).
Blinding
When assessing the risk of bias of the included trials fromblinding,
it should be noted that it is difficult to blindphysiotherapy trials. In
fact, for this intervention it would not have been possible to blind
either the participants or the clinicians administering treatment
to the intervention. It would only have been possible to blind the
outcome assessors.
We judged two trials to have a low risk of bias (Holland 2003;
Rodriguez Hortal 2016). The Holland trial employed an indepen-
dent data collector who was blinded to the treatment order to ob-
tain all measurements (Holland 2003). There is evidence of blind-
ing in the Rodriguez Hortal trial as pulmonary laboratory tech-
nicians (who measured the lung function tests) were blinded to
physiotherapy treatment; furthermore, research nurses, who took
vital signs, were blinded to treatment. A physiotherapist super-
vised and conducted all monthly treatment sessions and weekly
phone calls; it is unclear if the 6MWTwas assessed by the research
physiotherapist, however we still judge this trial to have a low risk
of bias (Rodriguez Hortal 2016).
We judged there to be an unclear risk of bias in five trials (Fauroux
1999; Gozal 1997; Kofler 1998; Placidi 2006; Young 2008). Fau-
roux stated that participants’ subjective impressions were evalu-
ated by individuals who were not involved in the trial and were
unaware of the treatment regimen; but it was not reported who
was responsible for collecting and weighing secretions or perform-
ing lung function testing, therefore the trial is still judged to have
an unclear risk of bias (Fauroux 1999). Gozal stated that while
participants were aware of the intervention being administered; all
were reportedly unaware of the purpose of the trial with partici-
pants and sleep technicians blinded to the results until completion
of the third night (Gozal 1997). Data collection was not described
at all by one trial as it was only reported as an abstract (Kofler
1998). One trial reported that physiotherapists collected sputum
and the technician was blinded to physiotherapy treatment, but it
is not reported whowas responsible for weighing sputum or collat-
ing cough information induced by the treatment (Placidi 2006).
There is evidence of blinding in the Young trial only for partici-
pants receiving either oxygen or room air, so we judge the risk of
bias for this to be unclear (Young 2008).
We judged there to be a high risk from a lack of blinding in
three trials (Dwyer 2015; Lima 2014;Milross 2001). Dwyer states
that the assessors where not blinded to treatment group allocation
(Dwyer 2015). There was no evidence of blinding of assessors,
investigators or participants in the published report of two trials
(Lima 2014; Milross 2001).
Incomplete outcome data
We judged there to be a low risk of bias for nine trials (Dwyer
2015; Fauroux 1999; Holland 2003; Kofler 1998; Lima 2014;
Milross 2001; Placidi 2006; Rodriguez Hortal 2016; Young 2008).
Two trials provided information on drop outs: Holland reported
one participant dropped out at the start of the trial because of
pain on respiratory muscle testing (Holland 2003); and Young
reported two participants dropped out (one withdrew consent due
to a pneumothorax on air and one from the NIV group withdrew
due to not tolerating the mask) (Young 2008). All participants
were accounted for in seven trials (Dwyer 2015; Fauroux 1999;
Kofler 1998; Lima 2014; Milross 2001; Placidi 2006; Rodriguez
Hortal 2016). There were treatment deviations reported in two
trials (Milross 2001; Young 2008). In the Milross trial this was
because one participant could not tolerate the increases in IPAP
(Milross 2001); in the Young trial, two participants experienced
aerophagia which resolved when the IPAP was reduced by 2 cm
H 0 (Young 2008).
One trial was judged as having an unclear risk of bias (Gozal 1997).
Gozal did not explicitly state that intention-to-treat was not used,
but results are based on the six participants who completed the
trial (Gozal 1997).
Selective reporting
We judged there to be a low risk of bias for nine trials since we
were not able to identify any selective outcome reporting when we
compared the ’Methods’ section to the ’Results’ section for each
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trial published in full (Fauroux 1999; Gozal 1997; Holland 2003;
Lima 2014; Milross 2001; Placidi 2006; Rodriguez Hortal 2016;
Young 2008).
As Kofler is published in abstract form only and we have been
unable to compare the trial protocol to the results presented, it is
unclear whether all outcome measures have been reported and the
risk of bias is unclear (Kofler 1998).
Other potential sources of bias
The methods of statistical analysis were described in nine trials,
thereforewe judged these trials to have a low risk for other potential
sources of bias (Dwyer 2015; Fauroux 1999; Gozal 1997; Holland
2003; Lima 2014; Milross 2001; Placidi 2006; Rodriguez Hortal
2016; Young 2008). The analysis methods were not described in
the Kofler trial abstract, leading to an unclear risk of bias (Kofler
1998).
Effects of interventions
Due to variations in the type and duration of trials, times at
which outcomes were measured, different methods of reporting
outcomes, omission of data relating to either mean change from
baseline for each group and the standard deviation (SD) or stan-
dard error (SE) it was not possible to pool data for many of the
outcomes.
There are discrepancies in some of the results reported between
the original trial analyses and our analyses in theData and analyses
section. These discrepancies may be due to some or all of the fol-
lowing reasons. As already mentioned, due to restrictions on the
data that were available, the method that we used for some of the
analysis was to treat the cross-over trials as if they were parallel
trials (see Unit of analysis issues). In two of the trials, non-para-
metric tests were used to analyse the original data (Gozal 1997;
Milross 2001), but the methods used for the analysis within this
review assume normality of the data, which may not have been an
appropriate assumption. We have been unable to confirm which
statistical method was used in one trial (Kofler 1998). Where dis-
crepancies have been found, the results from both the original
analysis and Data and analyses are detailed in the text. Some trials
reported statistical or non-statistical differences between groups,
but did not provide adequate data (means and SDs) that could be
analysed in the RevMan software (RevMan 2014). When this has
occurred the information from the original trial has been included
in the text.
A full list of abbreviations can be found in the additional tables
section (Table 1).
The role of NIV as a method of airway clearance
There are six trials included under this intervention (Dwyer
2015; Fauroux 1999; Holland 2003; Kofler 1998; Placidi 2006;
Rodriguez Hortal 2016). In trials comparing NIV to other meth-
ods of airway clearance techniques, the authors tested for hetero-
geneity between results for lung function using the I² statistic but
given the insufficient number of trials included in this review and
the lack of meta-analysis the value of I² is 0%. A sensitivity analy-
sis was performed entering the Placidi data separately so that par-
ticipants were not counted twice i.e. either chest physiotherapy
including directed cough or chest physiotherapy including PEP
and both data were reported.
Primary outcomes
1. Mortality
No trials looked at mortality.
2. QoL
Three trials (n = 73) reported on this outcome (Dwyer 2015;
Fauroux 1999; Placidi 2006). Only one trial (n = 40) used a CF-
specific questionnaire and reported the data in a form we were
able to analyse (Dwyer 2015). There was no difference between
groups reported in the physical domain, MD -4.00 (95% CI -
20.05 to 12.05) or the health domain, MD 3.00 (95% CI -12.52
to 18.52), but there was a difference in the respiratory domain
favouring NIV,MD 11.00 (95%CI 0.58 to 21.42) (Analysis 1.1).
All three trials reported fatigue (Dwyer 2015; Fauroux 1999;
Placidi 2006), but only one trial reported data we could analyse
(Dwyer 2015). This trial used the Schwartz fatigue scale and our
analysis showed no difference in fatigue, MD -6.00 (95% CI -
13.27 to 1.27) (Analysis 1.2). However, the publication reports
significantly less fatigue in the NIV group, MD -6 (95% CI -
11 to -1) when adjusted for admission values (Dwyer 2015). The
remaining two trials reported narratively. In the Fauroux trial, 15
out of 16 participants felt less tired after theNIV session compared
to the chest physiotherapy session (Fauroux 1999). In the Placidi
trial participants reported feeling less tired after NIV than after
PEP (Placidi 2006).
3. Symptoms of sleep-disordered breathing
No trials looked at symptoms of sleep-disordered breathing.
Secondary outcomes
1. Lung function
Forced expiratory volume at one second (FEV ), forced vital
capacity (FVC) and forced mid-expiratory flow rate (FEF25−75)
were reported in six trials (Dwyer 2015; Fauroux 1999; Holland
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2003; Kofler 1998; Placidi 2006; Rodriguez Hortal 2016). There
were no primary data available for one trial, which was published
as a abstract only (Kofler 1998). This trial reported that there
was no significant difference in post-intervention lung function
between the groups (Kofler 1998).
a. FEV
A total of five trials reported on FEV ; two of these reported
FEV in litres (L) post-treatment (Holland 2003; Placidi 2006)
and three trials reported FEV % predicted post-treatment
(Dwyer 2015; Fauroux 1999; Rodriguez Hortal 2016).
After oneweek therewas nodifference between groups eitherwhen
NIV was compared to directed cough (n = 43), MD -0.03 L (95%
CI -0.17 to 0.12) or to PEP (n = 17) MD -0.05 L (95% CI -0.22
to 0.12) (Analysis 1.3).
One trial (n = 16) reported NIV compared to directed cough at
up to one week (Fauroux 1999) and found no difference between
treatment groups, MD -0.90% (95% CI -17.41 to 15.61). A fur-
ther trial (n = 40) presented results for FEV % predicted in a
comparison of NIV to all ACTs combined at up to two weeks
(Dwyer 2015); there was no difference between the groups, MD
1.30% (95% CI -7.32 to 9.92) (Analysis 1.4). The trial paper also
reported there was no difference between the NIV and the chest
physiotherapy groups in the daily rate of improvement in FEV
% predicted, MD 0.13% per day (95% CI -0.03 to 0.28) (Dwyer
2015). One longer-term trial (n = 32) compared NIV to PEP over
three months and reported FEV % predicted post-treatment
(Rodriguez Hortal 2016). Our analysis showed a significant dif-
ference in absolute post-treatment values, MD -13.00% (95% CI
-21.32 to -4.68) (Analysis 1.4), but the original publication re-
ported no difference.
b. FVC
Four trials reported FVC post-treatment; two (n = 43) reported
FVC L (Holland 2003; Placidi 2006) and two (n = 32) reported
FVC%predicted (Fauroux 1999; Rodriguez Hortal 2016).When
data were analysed, there was no statistical difference in FVC L at
up to one week for the comparison of NIV to directed cough MD
0.00 L (95% CI -0.30 to 0.30) or for the comparison of NIV to
PEPMD -0.07 L (95% CI -0.47 to 0.33) (Analysis 1.5). For FVC
% predicted, there was no difference at one week between NIV
and directed cough, MD0.40% (95%CI -13.46 to 14.26). At the
up to three-month time point PEP was significantly better than
NIV, MD -17.00% (95% CI -26.80 to -7.20) (Analysis 1.6), but
the original publication reported no difference (Rodriguez Hortal
2016).
c. FEF25−75
Three trials (n = 59) reported on FEF25−75 post-treatment; two
reported L (Holland 2003; Placidi 2006) and one % predicted
(Fauroux 1999). Comparing NIV to directed cough, there was no
statistical difference in FEF25−75 L found between groups post-
treatment at up to one week, MD -0.00 L (-0.08 to 0.07); this was
also true for the comparison of NIV to PEP at the same time point,
MD 0.00 L (95% CI -0.07 to 0.07) (Analysis 1.7). The study
comparing NIV to directed cough and reporting FEF25−75 %
predicted again showed no statistical difference in post-treatment
at up to one week between groups, MD -6.00% (95% -28.03 to
16.03) (Analysis 1.8).
d. Maximal inspiratory mouth pressure (PImax)
This outcome was reported in three trials (n = 82) (Dwyer 2015;
Fauroux 1999; Holland 2003); two of which (n = 56) provided
data we were able to analyse (Dwyer 2015; Fauroux 1999). Fau-
roux reported that PImax decreased significantly after the chest
physiotherapy (all techniques combined) session, but increased
significantly after the NIV session (Fauroux 1999). Our analysis
showed that post-treatment values for PImax at up to one week
were significantly greater after NIV than chest physiotherapy,MD
23.00 cm H O (95% CI 18.01 to 27.99) (Analysis 1.9). In the
Dwyer trial at up to two weeks (at discharge), our analysis showed
no difference between the NIV and the chest physiotherapy (all
techniques combined) groups whenmeasured after the physio ses-
sion, MD -8.00 cm H O (95% CI -31.05 to 15.05) (Analysis
1.9). The original publication reported that on Day 2 of the ad-
mission, PImax worsened following standard chest physiotherapy
and improved following NIV-assisted chest physiotherapy giving
a MD 8 cm H O (95% CI 2 to 14) (Dwyer 2015).
In the original paper, Holland reported that there was a significant
reduction in PImax following standard treatment (P = 0.04), but
PImaxwasmaintained followingNIV treatment, which resulted in
a significant difference compared with standard treatment PImax,
MD 9.04 cm H O (95% CI 4.25 to 13.83) (Holland 2003).
e. Maximal expiratory mouth pressure (PEmax)
This outcome was reported in three trials (n = 82) (Dwyer 2015;
Fauroux 1999;Holland2003); twoofwhich (n=56) provideddata
we were able to analyse (Dwyer 2015; Fauroux 1999) (Analysis
1.10). Fauroux reported that at up to one week PEmax decreased
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significantly after the chest physiotherapy (all techniques com-
bined) session, but after the NIV session there was a non-signif-
icant increase in PEmax (Fauroux 1999). Post-treatment values
for PEmax were significantly greater after NIV than chest physio-
therapy, MD 10.50 cm H O (95% CI 6.18 to 14.82) (Analysis
1.10). The Dwyer trial reported that at up to two weeks there was
no difference in PEmax between the NIV and the chest physio-
therapy (all techniques combined) groups, MD -20.00 cm H O
(95% CI -47.42 to 7.42) (Analysis 1.10); the original publication
reported the difference in PEmax between groups following chest
physiotherapy on Day 2 of admission was MD 6 cmH O (95%
CI -3 to 15) and whenmeasured again before and after chest phys-
iotherapy one week into the admission and on discharge from hos-
pital, there was no difference in change in PEmax between groups
(Dwyer 2015).
Holland reported that PEmax did not change significantly follow-
ing standard treatment, but did increase following NIV, MD 8.04
cm H O (95% CI 0.61 to 15.46) (Holland 2003).
f. Tidal volume
One trial (n = 16) reported that tidal volume increased frommean
(SD) 0.42 (0.01) L to 1.0 (0.02) L after the NIV physiotherapy
session, but there were no data provided for the control session so
we were unable to enter these data in the analysis (Fauroux 1999).
g. Respiratory rate
One trial (n = 16) reported that respiratory rate was significantly
lower during NIV than during chest physiotherapy (no data avail-
able) (Fauroux 1999).
h. Airway resistance
One trial (n = 16) reported that when comparing chest physio-
therapy with NIV, there was no statistical difference in airway re-
sistance (% predicted) between groups post-treatment, MD -9.00
(95% CI -31.35 to 13.35) (Fauroux 1999) (Analysis 1.11).
i. Lung clearance index (LCI)
One trial reported on LCI after three months (Rodriguez Hortal
2016). Our analysis of absolute post-treatment values showed
there was no difference between the NIV and PEP, MD -0.56 cm
H O (95% CI -2.31 to 1.19) (Analysis 1.12); however, the orig-
inal publication reported a significant decrease in LCI in the NIV
group compared to the PEP group (change data not available for
our analysis) (Rodriguez Hortal 2016).
2. Measures of gas exchange
This outcome was reported in five trials (n = 111) during airway
clearance sessions (Fauroux 1999; Holland 2003; Kofler 1998;
Placidi 2006; Rodriguez Hortal 2016). In the Fauroux trial (n =
16), the saturation of haemoglobin with oxygen in arterial blood
(SpO )wasmeasured and recorded in numerousways:mean oxy-
gen saturation (mSpO ); the largest fall expressed in the absolute
value of SpO (nadirSpO ); the largest fall expressed as the dif-
ference with the SpO just before the manoeuvre (*SpO max);
the mean of *SpO max during the whole chest physiotherapy
(*SpO mean) (Fauroux 1999).We have chosen to report on one
of these from this trial i.e. *SpO mean. Indices of oxygenation
were significantly lower during chest physiotherapy than during
NIV, *SpO mean MD 1.00 (95% CI 0.29 to 1.71) (Analysis
1.13).
Kofler (n = 20) reported the change in SpO during treatment
(Kofler 1998). There was a significantly greater improvement in
SpO following NIV versus chest physiotherapy including PEP,
MD 1.16% (95% CI 0.08 to 2.24) (Analysis 1.14).
The analysis of the data from the Placidi trial (n = 17) showed
there was no significant difference in SpO after airway clearance
when comparing NIV to chest physiotherapy including directed
cough, MD 0.20% (95% CI -0.74 to 1.14), or when comparing
NIV to chest physiotherapy including PEP, MD -0.10% (95% CI
-0.98 to 0.78) (Placidi 2006) (Analysis 1.15).
The Holland trial (n = 26) did not report data that we were able
to present in our analysis. It reported that the mean SpO (P <
0.001) and the minimum SpO (P = 0.007) were significantly
lower during standard treatment than during NIV treatment. The
addition of NIV resulted in a significant reduction in the propor-
tion of treatment time when SpO was below 90% (P = 0.001)
(Holland 2003).
One trial (n = 32) reported on the partial pressure of carbon diox-
ide (PaCO ) (Rodriguez Hortal 2016). Our analysis showed no
difference between NIV and PEP in PaCO , MD 0.02 (95% CI
-0.39 to 0.43) (Analysis 1.16).
3. Respiratory symptom scores and sputum production
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The Borg breathlessness score was reported in one trial (n = 26)
(Holland 2003); there was no statistical difference between groups
post-treatment,MD -0.43 (95%CI -1.46 to 0.60) (Analysis 1.17).
A second trial (n = 40) reported breathlessness using a visual ana-
logue scale (VAS) measured in cm (Dwyer 2015), but found no
difference between the NIV or the chest physiotherapy groups at
up to two weeks, MD -0.11 (95% CI -0.76 to 0.53) (Analysis
1.17).
Sputum production was reported in four trials (n = 99) (Dwyer
2015; Fauroux 1999; Holland 2003; Placidi 2006). Three trials
(n = 59) reported on the amount of wet weight sputum expecto-
rated (Fauroux 1999;Holland 2003; Placidi 2006).When the data
from the comparison of NIV with chest physiotherapy including
directed coughing were analysed there was no statistical difference
between the groups, MD -0.69 g (95% CI -3.06 to 1.67); likewise
for the comparison of NIV to chest physiotherapy including PEP,
MD -2.58 g (95%CI -6.11 to 0.95) (Analysis 1.18). Furthermore,
Fauroux reported that 10 out of 16 participants considered expec-
toration was easier with NIV, four out of 16 participants did not
perceive any difference and two participants did not expectorate
(Fauroux 1999).
Placidi (n = 17) reported dry weight sputum (Placidi 2006). The
trial found no significant difference between the NIV and the
chest physiotherapy including directed cough groups, MD -0.09 g
(95%CI -0.56 to 0.38), nor betweenNIV and chest physiotherapy
including PEP, MD -0.06 g (95% CI -0.46 to 0.34) (Analysis
1.19).
One trial (n = 40) reported the daily perceived sputum volume
using a VAS (cm) (Dwyer 2015). The trial found no difference be-
tween the NIV and chest physiotherapy groups, MD -0.50 (95%
CI -1.67 to 0.67) (Analysis 1.20).
The Dwyer trial also reported on Pseudomonas aeruginosa bacterial
density (Dwyer 2015) and showed a non-significant difference
between the NIV and the chest physiotherapy at up to two weeks,
MD -0.94 (95% CI -1.90 to 0.02) (Analysis 1.21).
4. Exercise tolerance
One trial (n = 40) reported on exercise tolerance using the 25-level
modified shuttle test (Dwyer 2015). Analysis of data showed no
difference between the NIV and chest physiotherapy groups at up
to twoweeks,MD-15.00m (95%CI -260.00 to 230.00) (Analysis
1.22). The same trial also used a VAS to report on perceived energy
levels (Dwyer 2015); there was no difference found between the
groups, MD 0.00 (95% CI -1.22 to 1.22) (Analysis 1.23).
One trial (n = 32) reported the 6MWT (Rodriguez Hortal 2016);
our analysis of the data showed no difference between NIV and
PEP groups, MD 6.00 (95% CI -53.92 to 65.92) (Analysis 1.24).
5. Impact on health resources
One trial (n = 40) reported on the number of days spent in hospital
and the time to the next admission (Dwyer 2015). There was no
difference between theNIV and chest physiotherapy groups in the
length of hospital stay, MD -0.05 days (95% CI -3.06 to 2.06)
(Analysis 1.25) or in the time to the next admission, MD 26 days
(95% -85.61 to 137.61) (Analysis 1.26).
6. Measures of nocturnal polysomnography
No trials looked at nocturnal polysomnography.
7. Effect on nutrition and weight
No trials looked at nutrition and weight.
8. Measures of right-sided cardiac function
No trials looked at right-sided cardiac function.
9. Cost
No trials looked at cost.
10. Adherence to treatment and preference
Four of the six trials comparing NIV to other airway clearance
techniques included information about subjective response to
NIV (Fauroux 1999; Holland 2003; Kofler 1998; Placidi 2006).
In three trials (n = 62) more participants stated that they pre-
ferredNIV to another method of airway clearance (Fauroux 1999;
Holland 2003; Kofler 1998). In one trial, 14 out of 16 participants
stated that they preferred NIV to chest physiotherapy and two
participants had no preference (Fauroux 1999). In a further trial,
15 out of 26 participants preferred treatment with NIV, eight out
of 26 stated that they preferred standard treatment and three had
no preference (Holland 2003). Kofler reported that 12 out of 20
participants preferred NIV, five out of 20 participants preferred
PEP and three out of 20 participants had no preferences (Kofler
1998). These results are summarised as follows:
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Trial Prefers NIV Prefers alternative ACT No preference Total participants
Fauroux 1999 14 2 16
Holland 2003 15 8 3 26
Kofler 1998 12 5 3 20
Total 41 13 8 62
In the Placidi trial (n = 17), no statistical difference was seen in
subjective effectiveness scores between chest physiotherapy (in-
cluding PEP) and NIV (Placidi 2006).
Although not formally measured in the Dwyer trial (n = 40), the
addition of NIV to chest physiotherapy was well-tolerated; only
one out of 19participants in theNIVgroup refusedNIV treatment
due to poor tolerance (Dwyer 2015).
Furthermore, Fauroux (n = 16) also reported that the physiothera-
pists found it easier to perform chest physiotherapy while the per-
son was on NIV in 14 out of 16 participants, but did not perceive
any difference in two participants (Fauroux 1999).
11. Adverse events
Three trials did not make any comments on negative or adverse ef-
fects (Fauroux 1999; Placidi 2006; Rodriguez Hortal 2016). Two
trials reported that there were no untoward effects in any partici-
pant (Kofler 1998; Dwyer 2015). Holland reported that one par-
ticipant withdrew at the beginning of the trial because of pain on
respiratory muscle testing (Holland 2003).
The role of NIV in overnight ventilation
There are three trials (n = 27) included under this intervention:
two single-night trials (n = 19) (Gozal 1997; Milross 2001) and
one short-term trial lasting six weeks (n = 8) (Young 2008).
Primary outcomes
1. Mortality
No trials reported on mortality.
2. QoL
One short-term trial (n = 8) assessedQoL using a CF-specific QoL
questionnaire (Young 2008). There was no significant difference in
the chest symptom score betweenNIV and oxygen,MD3.0 (95%
CI -15.73 to 21.73) (Analysis 2.1) or the transitional dyspnoea
index score, MD 1.4 (95%CI -0.29 to 3.09) (Analysis 2.2). There
was no significant difference in the chest symptom score between
NIV and room air, MD 7.00 (95% CI -11.73 to 25.73) (Analysis
3.1); however, in the original trial this was reported as significant
P < 0.002. There was a significant difference in the transitional
dyspnoea index score between NIV and room air, MD 2.90 (95%
CI 0.71 to 5.09) (Analysis 3.2).
3. Symptoms of sleep-disordered breathing
In the short-term trial (n = 8), daytime sleepiness wasmeasured as a
primary outcome (Young 2008). For the comparisonbetweenNIV
and oxygen, there was no significant difference between groups
for either the daytime Epworth sleepiness score, MD 00.0 (95%
CI -5.57 to 5.57) or the daytime sleepiness global Pittsburg sleep
quality index (PSQI) score, MD 00.0 (95% CI - 2.62 to 2.62)
(Analysis 2.3). Likewise, for the comparison between NIV and
room air, there were no significant differences between groups for
either the daytime Epworth sleepiness score, MD 00.0 (95% CI
-5.07 to 5.07) or the PSQI score, MD -1.0% (95% CI -4.04 to
2.04) (Analysis 3.3).
Secondary outcomes
1. Lung function
a. Lung function during sleep
One single-night trial (n = 13) reported on lung function during
sleep (Milross 2001). The data have been entered into the analysis
using GIV and as can be seen from the graphs, several results
were non-significant and these have not been reported in the text
(Analysis 2.4; Analysis 3.4).
When comparing NIV and oxygen, our analysis showed a signifi-
cant difference inminute ventilation (VI) in favour of NIV during
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REM sleep,MD 1.48 L/m (95% CI 0.74 to 2.22); but in the orig-
inal report this did not reach statistical significance. The difference
between groups during NREM sleep was not significant. A sig-
nificant difference in tidal volume (VT) was seen between groups
during both REM sleep, MD 0.08 L (95% CI 0.04 to 0.12) and
NREM sleep, MD 0.03 L (95% CI 0.01 to 0.05) (Analysis 2.4).
When comparing NIV and room air, there was a significant dif-
ference in VI in favour of NIV during REM sleep, MD 1.56 L/
m (95% CI 0.05 to 3.07); as for the comparison of NIV and
oxygen, in the original report this did not reach statistical signifi-
cance. There was also a significant difference in VI between NIV
and room air during NREM sleep, MD 1.04 L/m (95% CI 0.37
to 1.17). A significant difference in VT between groups was seen
during REM sleep, MD 0.10 L (95% CI 0.04 to 0.16), but not
during NREM sleep (Analysis 3.4).
Milross also measured respiratory rate during sleep in the single-
night trial (Milross 2001). In the comparison of NIV and oxygen,
there was a significant difference between groups in respiratory rate
during REM sleep, MD -1.84 breaths per minute (bpm) (95% CI
-3.25 to -0.43), but not during NREM sleep (Analysis 2.5). This
was also true for the comparison of NIV to room air, where there
was a significant difference between groups during REM sleep,
MD -2.64 bpm (95% CI -3.70 to -1.58), but not during NREM
sleep (Analysis 3.5). There was no significant difference in mean
respiratory rate during slow wave sleep between NIV and oxygen,
MD -6.00 bpm (95% CI -22.7 to 10.7) (Analysis 2.5) and NIV
and room air, MD 0.00 bpm (95% CI -5.07 to 5.07) (Analysis
3.6).
b. Lung function while awake
One short-term trial (n = 8) reported a number of different mea-
sures of lung function for the comparisons between NIV and oxy-
gen and betweenNIV and room air (Young 2008).When compar-
ing NIV to oxygen, there were no significant differences in FEV
% predicted, MD 1.00% (95% CI -8.13 to 10.13) or in FVC %
predicted, MD 4.00% (95% CI -11.22 to 19.22) (Analysis 2.6).
When comparing NIV to room air, there were likewise no signif-
icant differences in FEV % predicted, MD 1.00% (95% CI -
8.62 to 10.62) or in FVC % predicted, MD 4.00% (95% CI -
10.32 to 18.30) (Analysis 3.8).
2. Measures of gas exchange
See also ’Measures of nocturnal polysomnography’.
The short-term trial (n = 8) looked at awake arterial blood gases
(Young 2008).
When comparing NIV to oxygen there were no significant dif-
ferences between groups for: pH, MD 0.00 (95% CI -0.03 to
0.03) (Analysis 2.7); PaO , MD -4.00 mmHg (95% CI -13.43
to 5.43) (Analysis 2.8); PaCO , MD -1.00 mmHg (95% CI -
7.10 to 5.10) (Analysis 2.9); HCO , MD 0.00 mmol/L (95%
CI -3.14 to 3.14) (Analysis 2.10); and SaO %, MD -2.00 %
(95% CI -6.06 to 2.06) (Analysis 2.11). Similarly, in the com-
parison of NIV and room air there were no significant differ-
ences between groups for: pH, MD 0.01 (95% CI -0.02 to 0.04)
(Analysis 3.9); PaO , MD -2.00 mmHg (95% CI -8.58 to 4.58)
(Analysis 3.10); PaCO , MD -2.00 mmHg (95% CI -8.10 to
4.10) (Analysis 3.11); HCO ,MD0.00 mmol/L (95%CI -2.55
to 2.55) (Analysis 3.12); and SaO %, MD -1.00 % (95% CI -
4.62 to 2.62) (Analysis 3.13).
The short-term trial (n = 8) looked at awake arterial blood gases
(Young 2008) but found no significant difference for any outcome
measure in either comparison as summarised in the table below:
Comparison Outcome Result Analysis
NIV compared to oxygen pH MD 0.00 (95% CI -0.03 to 0.03) Analysis 2.7
PaO MD -4.00 mmHg (95% CI -13.43 to 5.
43)
Analysis 2.8
PaCO MD -1.00 mmHg (95% CI -7.10 to 5.10) Analysis 2.9
HCO MD 0.00 mmol/L (95% CI -3.14 to 3.14) Analysis 2.10
SaO % MD -2.00 % (95% CI -6.06 to 2.06) Analysis 2.11
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(Continued)
NIV compared to room air pH MD 0.01 (95% CI -0.02 to 0.04) Analysis 3.9
PaO MD -2.00 mmHg (95% CI -8.58 to 4.58) Analysis 3.10
PaCO MD -2.00 mmHg (95% CI -8.10 to 4.10) Analysis 3.11
HCO MD 0.00 mmol/L (95% CI -2.55 to 2.55) Analysis 3.12
SaO % MD -1.00 % (95% CI -4.62 to 2.6) Analysis 3.13
3. Sputum production
No trials looked at sputum production.
4. Exercise tolerance
One short-term trial (n = 8) looked at exercise tolerance (Young
2008). There was no significant difference in the modified shut-
tle walk test (MSWT) between NIV and oxygen, MD 56.00 m
(95% CI -76.74 to 188.74) (Analysis 2.12). For the comparison
between NIV and room air, the analysis in RevMan shows no sig-
nificant difference in the MSWT, MD 78.00 m (95% CI -62.52
to 218.52) (Analysis 3.14). However, the original paper reported
a significant difference in the MSWT between the NIV and room
air intervention, MD 83.00 m (95% CI 21 to 144) (Young 2008).
5. Impact on health resources
No trials looked at the impact on health resources.
6. Measures of nocturnal polysomnography
Two single-night trials (n = 19) (Gozal 1997; Milross 2001) and
the six-week trial (n = 8) (Young 2008) looked at measures of sleep
polysomnography.
a. Total sleep time (TST)
This outcome was reported in one single-night trial (n = 6) (Gozal
1997) and the six-week trial (n = 8) (Young 2008).
In the single-night trial there was no statistical difference in TST
when NIV was compared to supplemental oxygen (Gozal 1997),
MD 4.00 min (95% CI -29.39 to 37.39) (Analysis 2.13) or when
it was compared to room air, MD 12.00 min (95% CI -33.56 to
57.56) (Analysis 3.15).
The six-week trial also reported no statistical difference in TST
when comparingNIV to supplemental oxygen (Young 2008),MD
-22.00 min (95% CI -55.19 to 11.19) (Analysis 2.13) or when
comparing it to room air, MD -25.00 min (95% CI -69.57 to
19.57) (Analysis 3.15).
b. REM sleep architecture
Gozal (n = 6) reported no statistical difference in the absolute
amount of time spent in REM sleep, MD -13.00 min (95% CI
-43.25 to 17.25) or the % of TST spent in REM sleep, MD
-3.00 (95% CI -9.88 to 3.88) when NIV was compared with
supplemental oxygen (Analysis 2.14). Young (n = 8) also showed
no statistical difference in the time in REM sleep expressed as a
% TST at six weeks, MD 2.00 min (95% CI -5.10 to 9.10) when
NIV was compared with supplemental oxygen (Analysis 2.14).
In our analysis of NIV compared to room air, there was no statisti-
cal difference in the absolute time spent in REM sleep, MD 10.00
min (95% CI -13.37 to 33.37) or the % TST spent in REM sleep,
MD 3.00 min (95% CI -1.67 to 7.67) (Analysis 3.16). However,
in the original trial both the amount of REM sleep and the%TST
spent in REM sleep were significantly greater in the NIV night
than in the room air night (Gozal 1997). At six weeks, Young
reported no statistical difference in time in REM sleep expressed
as a % TST, MD 2.00 (95% CI -5.59 to 9.59) when NIV was
compared with room air (Analysis 3.16).
c. Sleep latency
Sleep onset latency is the length of time that it takes to accom-
plish the transition from full wakefulness to sleep, normally to the
lightest of the non-REM sleep stages. Sleep latency was reported
in two single-night trials (n = 19) (Gozal 1997; Milross 2001) and
one six-week trial (n = 8) (Young 2008). After one night, there
was no statistical difference in sleep latency with NIV compared
to supplemental oxygen, MD 2.93 min (95% CI -0.32 to 6.19);
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this was also true after six weeks, MD -5.00 min (95% CI -19.17
to 9.17) (Analysis 2.15).
When comparing NIV to room air, the two single-night tri-
als showed no statistical difference in sleep latency between the
groups, MD -2.63 min (95% CI -7.37 to 2.11); again, this was
also not significant at six weeks, MD -3.00 min (95% CI -19.88
to 13.88) (Analysis 3.17).
d. Nocturnal oxygen levels
The Gozal and Young trials (n = 14) reported mean SpO (Gozal
1997; Young 2008). Our analysis of the Gozal data showed no
statistically significant difference in mean SpO between NIV
and supplemental oxygen during either REM sleep, MD -2.00%
(95% CI -4.88 to 0.88) or NREM sleep, MD -1.00% (95% CI -
2.79 to 0.79) (Analysis 2.16); although the original trial reported
SpO to be significantly lower during REM and NREM sleep on
the NIV night (Gozal 1997). When Young (n = 8) compared NIV
to oxygen for six weeks, the mean SpO for TST was not statis-
tically significant between groups, MD -1.00 % (95% CI -3.62
to 1.62) (Analysis 2.16). Young also reported nocturnal hypoxia,
defined as SpO below 90% (Young 2008) and showed no sig-
nificant difference between NIV and oxygen for TST with SpO
below 90%, MD 13.00 % (95% CI -12.95 to 38.95) (Analysis
2.16). Milross (n = 13) reported the proportion of time spent with
SpO over 90% during TST, REM and NREM (Milross 2001).
Analysing these data using GIV, there were no statistically signif-
icant differences between NIV and supplemental oxygen either
during TST, MD -2.54 min (95% CI -9.59 to 4.50); in REM
sleep, MD 0.65 min (95% CI -8.94 to 10.25); or in NREM sleep,
MD -0.84 min (95% CI -7.95 to 6.26) (Analysis 2.17).
Comparing NIV versus room air, our analysis of data from the
Gozal trial showed mean SpO to be significantly greater in the
NIV group during both REM sleep, MD 9.00% (95% CI 2.91
to 15.09) and NREM sleep, MD 5.00% (95% CI 0.69 to 9.31)
(Analysis 3.18); although this difference was not significant in the
primary trial analysis (Gozal 1997). In contrast to this, the Young
trial showed no significant difference in mean SpO for TST
between NIV and room air at six weeks, MD 3.00 (95% CI -1.04
to 7.04) (Analysis 3.18). When analysing data from the Milross
trial for the comparison of NIV to room air, we found that SpO
was greater than 90% for significantly more time in theNIV group
during TST, MD 27.58 min (95% CI 7.83 to 47.33); during
REM sleep, MD 34.53 min (95% CI 15.00 to 54.06); and during
NREM sleep, MD 26.21 min (95% CI 6.24 to 46.18) (Analysis
3.19). The original trial reported that SpO was over 90% for
significantly less time during TST and REM sleep on the room
air night versus the oxygen or NIV night and that there was no
significant difference in percentage of time spent with SpO over
90% in NREM during the NIV night or the oxygen night and the
room air night (Milross 2001). Analysis of the data from the Young
trial for nocturnal hypoxia when comparing NIV with room air
showed no significant difference between treatment groups, MD
-25.00 (95% CI -66.90 to 16.90) (Analysis 3.18)
e. Nocturnal carbon dioxide levels
In theGozal trial (n = 6) transcutaneous carbon dioxide (TcCO )
on the NIV night was significantly lower than in the oxygen night
during REM sleep, MD -1.90 mmHg (95% CI -2.55 to -1.25)
and during NREM sleep, MD -1.40 mmHg (95% CI -2.19 to -
0.61) (Analysis 2.18). The Milross trial reported TcCO during
sleep in terms of change during different phases of sleep (Milross
2001). The change in TcCO from NREM to REM in the NIV
night was significantly less than in the oxygen night, MD -2.60
mmHg (95% CI -4.05 to -1.16) (Analysis 3.21); the original re-
port stated that NIV with oxygen “significantly attenuated the rise
in TcCO seen with REM sleep compared with both supple-
mental oxygen and room air” (Milross 2001). Milross and Young
also compared the maximum TcCO for NIV and supplemental
oxygen groups (Milross 2001; Young 2008). In the shorter trial,
Milross reported no significant difference between the two nights,
MD -2.08 mmHg (95% CI -10.64 to 6.48) (Analysis 2.19). In
the longer trial, Young reported a significantly lower maximum
pressure of transcutaneous carbon dioxide (PtCO ) during TST
with NIV compared to oxygen, MD -14.00 mmHg (95% CI -
23.22 to -4.78) (Analysis 2.20). Young also reported a significant
result for NIV compared to oxygen for both the mean change in
PtCO , MD -2.80 mmHg (95% CI -5.53 to -0.77) and the
mean change in partial pressure of carbon dioxide (PaCO ),MD
-7.30 mmHg (95% CI -11.51 to -3.09) (Analysis 2.18).
When comparing NIV to room air, Gozal reported that TcCO
in the NIV night was significantly lower during both REM, MD
-0.90 mmHg (95% CI -1.62 to -0.18) and during NREM, MD
-0.70 mmHg (95% CI -1.15 to -0.25) (Analysis 3.20). Milross
reported that the change in TcCO fromNREM to REM in the
NIV night was significantly less than in the room air night, MD -
2.31 mmHg (95% CI -3.30 to -1.32) (Analysis 3.21); the original
report stated that NIV with oxygen “significantly attenuated the
17Non-invasive ventilation for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
rise in TcCO seen with REM sleep compared with both supple-
mental oxygen and room air” (Milross 2001). Milross and Young
compared the maximum TcCO for NIV and room air groups
(Milross 2001; Young 2008). Milross reported a no difference be-
tween the NIV and room air groups, MD -0.73 mmHg (95%
CI -10.76 to 9.29) (Analysis 3.21). Young reported a significantly
lower maximum PtCO during TST for the NIV group com-
pared to the room air group, MD -16.00 mmHg (95% CI -30.15
to -1.85), but no significance difference between the two groups
for mean PtCO during TST, MD -9.0 mmHg (95% CI -19.05
to 1.05) (Analysis 3.22). In the same trial there was a significant
difference in mean change PtCO for NIV compared to room
air, MD -2.20 mmHg (95% CI -4.32 to -0.8), but no significant
difference for mean change PaCO for NIV compared to room
air, MD -3.30 mmHg (95% CI -6.73 to 0.13) (Analysis 3.20)
f. Episodes of hypopnoea
One single-night trial (n = 13) reported on this outcome (Milross
2001). The trial reports that in the NIV night the number of
episodes of hypopnoeas per hour were significantly lower than in
the oxygen night, relative rate (RR) 0.02 (95% CI 0.01 to 0.06)
(Analysis 2.21); likewise, these were significantly lower in theNIV
night than the room air night, RR 0.02 (95% CI 0.01 to 0.05)
(Analysis 3.23).
g. Heart rate
There was no significant difference in mean heart rate when NIV
was compared to oxygen, MD -6.00 bpm (95% CI -22.7 to 10.7);
NIV compared to room air, MD -9.00 bpm (95% CI -21.89 to
3.89), whereas in the original paper a significant difference was
reported (P = 0.05) (Young 2008) (Analysis 2.22) .
h. Respiratory rate
Only one trial (n = 8) reported on this outcome (Young 2008).
There was no significant difference in mean respiratory rate when
NIV was compared to oxygen, MD 1.00 bpm (95% CI -3.04 to
5.04) (Analysis 2.23).
7. Effect on nutrition and weight
No trials looked at nutrition and weight.
8. Measures of right-sided cardiac function
No trials looked at right-sided cardiac function.
9. Cost
No trials looked at cost.
10. Adherence to treatment and preference
Two trials (n = 14) looked at treatment preference (Gozal 1997;
Young 2008). Gozal reported that four out of six participants pre-
ferred oxygen to NIV, despite morning headache being present in
two participants following the oxygen night (Gozal 1997). The
Young trial reported that four out of eight participants rated oxy-
gen as the most comfortable, whilst two rated oxygen and air
equally comfortable (Young 2008). Four out of eight participants
preferred oxygen as long-term therapy whilst three preferred NIV;
no participants selected air as their preferred treatment (Young
2008).
11. Adverse events
One trial did not make any comments on negative or adverse ef-
fects (Gozal 1997). Two trials provided information about nega-
tive effects (Milross 2001; Young 2008). Milross reported conse-
quential deviations in treatment in one participant who was un-
able to tolerate increases in IPAP (Milross 2001). Young reported
that four participants withdrew in total: one participant withdrew
from the NIV arm of the trial as they did not tolerate NIV due to
mask discomfort; one participant withdrew following consent due
to developing a pneumothorax whilst on air, which was consid-
ered as coincidental; and two participants experienced aerophagia
which resolved when the IPAP was reduced by 2 cmH 0. (Young
2008).
The role of NIV during exercise
One cross-over trial (n = 13) explored the effect of NIV versus no
NIV during exercise (Lima 2014).
Primary outcomes
1. Mortality
This trial did not look at mortality (Lima 2014).
2. QoL
This trial did not look at health-related QoL (Lima 2014).
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3. Symptoms of sleep-disordered breathing
This trial did not look at sleep (Lima 2014).
Secondary outcomes
1. Lung function
Lung function data (FEV , FVC, FEF25−75, VT, VI and respira-
tory rate) and indices of ventilation (total time, inspiratory time,
expiratory time) were reported in the paper as median (interquar-
tile range (IQR)) values and so could not be analysed in RevMan.
The original paper reported that there were no between group
differences in lung function or these indices of ventilation (Lima
2014).
2. Gas exchange
These data were not reported in a way that could be analysed in
RevMan, but the original paper reports no significant difference in
SpO between groups after the treadmill walk test (TWT) (Lima
2014).
3. Respiratory symptom scores and sputum production
Lima reported perceived exertion using the Borg scale, but these
datawere not presented in away that could be analysed inRevMan.
The original paper reported no significant difference between the
groups immediately after the TWTs with or without NIV (Lima
2014).
4. Exercise tolerance
Lima reported a statistical difference in the distance walked when
exercising with NIV compared to exercising without NIV (P =
0.039); however, this difference was not significant when the data
were analysed inRevMan,MD28.46m (95%CI -34.04 to 90.95)
(Analysis 4.1).
5. Impact on health resources
This trial did consider the impact on health resources (Lima 2014).
6. Nocturnal polysomnography
This trial did not look at nocturnal polysomnography (Lima
2014).
7. Nutrition and weight
This trial did not look at nutrition or weight (Lima 2014).
8. Right-sided cardiac function
This trial did not look at cardiac function (Lima 2014).
9. Cost
This trial did not look at cost (Lima 2014).
10. Adherence to treatment and preference
This trial did not look at adherence to treatment or preference
(Lima 2014).
11. Adverse events
This trial did not report any adverse events (Lima 2014).
D I S C U S S I O N
Summary of main results
A total of 10 trials are included in the review. Six trials focused
on the role of non-invasive ventilation (NIV) as a method of air-
way clearance (Dwyer 2015; Fauroux 1999; Holland 2003; Kofler
1998; Placidi 2006; Rodriguez Hortal 2016); four of these were
single sessions (Fauroux 1999;Holland 2003; Kofler 1998; Placidi
2006), one took place during a two-week exacerbation period
(Dwyer 2015) and one over a three-month period (Rodriguez
Hortal 2016). Three trials looked at the role of NIV in overnight
ventilation; two were single-night trials (Gozal 1997; Milross
2001) and one lasted six weeks (Young 2008). The final trial fo-
cused on the role of NIV on exercise capacity for a single interven-
tion (Lima 2014). The review authors recognise that short-term
studies may not allow the participants in the studies sufficient time
to familiarise themselves with NIV and this is an important con-
sideration for future trials.
In a single physiotherapy session the use of NIV led to easier air-
way clearance in participants with stable moderate to severe dis-
ease and most participants preferred to use NIV for airway clear-
ance treatment. We were unable to find any evidence that NIV
increases sputum expectoration or improves lung function. There
is some evidence that the introduction of NIV to airway clear-
ance preserved muscle strength and improved expiratory muscle
strength. No deleterious effects on small airway function were ob-
served. In terms of airway clearance over a longer period of time,
e.g. among people hospitalised for an acute exacerbation of cystic
fibrosis (CF), the use of NIV as an adjunct to the airway clearance
regimen offers no clear benefit compared to no NIV. A more re-
cent trial has used the lung clearance index (LCI) to explore the
effect of NIV on ventilation inhomogeneity and this may be a po-
tentially useful outcome to explore the effect of airway clearance
and also improve understanding of mechanisms of action.
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In terms of overnight ventilatory support in a single nocturnal
treatment session, NIV offers benefits over oxygen or room air.
Nocturnal hypoventilation is an early marker of respiratory de-
terioration in advanced CF and can lead to the development of
daytime hypercapnia. By attenuating the decrease in ventricular
tachycardia and improving ventilation during sleepNIV decreases
hypoventilation in people with moderate to severe lung disease.
Nocturnal oxygen saturation (SpO ) may be increased by NIV
and oxygen or oxygen alone, but the increase in SpO with NIV
and oxygen is likely to occur without a concomitant increase in
transcutaneous carbon dioxide (TcCO ), as seen when people
receive oxygen alone. The respiratory rate on the NIV night was
significantly lower in rapid eye movement (REM) sleep than on
the room air or oxygen nights. In the trial by Gozal, four out of six
participants reported that they preferred oxygen therapy overnight
to NIV and oxygen (Gozal 1997). Milross found only one partic-
ipant in the group of 13 who was unable to tolerate sufficiently
high pressures to improve nocturnal ventilation (Milross 2001).
In terms of a longer period of overnight ventilation (six weeks),
NIV further demonstrated an improvement in nocturnal hyper-
capnic levels as well as ameaningful clinically important difference
in peak exercise capacity and exertional dyspnoea when compared
to room air. Young identified the improvement of peak exercise
capacity as important since it is a predictor of survival in adults
and children with CF (Young 2008). However, this six-week in-
tervention did not lead to a change in sleep architecture, lung
function or awake hypercapnic levels. With regard to preference,
four participants preferred oxygen as a long-term therapy, three
preferred NIV and none selected air as their preferred long-term
therapy (Young 2008).
In terms of exercise capacity, one study reported that the distance
walked increased significantly with NIV during a single session
comparing NIV to no NIV while walking (Lima 2014).
Overall, the results from included studies demonstrate that NIV
improves the physiological markers of early respiratory failure fol-
lowing a single nocturnal treatment session, with improvements in
exercise tolerance, selected aspects of quality of life and nocturnal
carbon dioxide levels when used over a longer period. Nocturnal
respiratory support with NIV has important implications for the
people with CF and advanced lung disease and may attenuate the
early effects and progression of respiratory failure. Further inves-
tigations over longer time periods are warranted to determine if
these changes will be sustained or have any influence on clinical
outcomes. Which subgroups benefit most from NIV intervention
also needs to be established.
Overall completeness and applicability of
evidence
The included trials covered all ranges of disease severity and status
and also all ages, so the results are likely applicable to the CF
population in general. It is notable that there was limited use of
important primary outcomes such as mortality, but this was likely
due to the length of studies in this review. Longer-term studies
are required to fully determine the effect on the review’s primary
outcomes. It is important to note that in the longest included
trial, Young did not address the issue of NIV in combination with
oxygen as opposed to NIV alone. The combination of NIV and
oxygen is more commonly considered in clinical practice in people
with CF and severe lung disease (Young 2008).
Quality of the evidence
One of the trials is in abstract form only and hence the data avail-
able from this trial are limited (Kofler 1998).
Nine of the trials were randomised cross-over trials and although
the existence of a carry-over effect was only investigated in one trial
(Holland 2003), each trial included a washout period between the
interventions.
All of the trials used random allocation. Four trials provided details
on the specific procedures used (Dwyer 2015; Lima 2014; Placidi
2006; Young 2008). The remaining six trials were described as
randomised, although details of how this was done are lacking
(Fauroux 1999; Gozal 1997; Holland 2003; Kofler 1998; Milross
2001; Rodriguez Hortal 2016).
None of the trials were double-blinded. However, this quality issue
must be considered in the context of the difficulty of blinding NIV
trials. It was clear in one trial that the outcome measurements were
performed by an independent assessor, who was not involved in
the delivery of the interventions (Holland 2003). In a further trial
it was clear that the majority of outcomes were measured by an
independent assessor (Rodriguez Hortal 2016).
These quality issues affect the internal validity of the trials. The
external validity of these trials is limited by the fact that six of the
trials in the review only assess the efficacy of a single-treatment
session of NIV and do not study the longer-term efficacy or safety
of NIV.
Potential biases in the review process
These have been minimised by a comprehensive search strategy
andbymultiple authors independently assessing trials for inclusion
and for risk of bias.
Agreements and disagreements with other
studies or reviews
These findings are in agreement with the British Thoracic Society
(BTS) and Intensive Care Society (ICS) Guideline for the ven-
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tilatory management of acute hypercapnic respiratory failure in
adults (Davidson 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Wehave found some limited evidence to support the use of NIV as
a clinical treatment in peoplewithCF.NIVmay be a useful adjunct
to other airway clearance techniques, particularly in people with
CF who have difficulty expectorating sputum or where fatigue or
respiratory muscle weakness is an issue. The trials in this review
demonstrate that when used together with overnight oxygen, NIV
improves gas exchange during sleep to a greater extent than oxygen
therapy alone in people with moderate to severe CF. Use of NIV
over a six-week period provided benefits over oxygen and room air
for those people with CF who experience daytime hypercapnia in
terms of exercise tolerance, dyspnoea and nocturnal gas exchange;
this effect of NIV has been demonstrated in only one clinical trial.
In children with stable disease, one trial of a single session of NIV
increased functional capacity.
Implications for research
There is a need for long-term multicentre randomised controlled
trials which are adequately powered to assess the impact of NIV
on quality of life and clinical disease progression when used as an
adjunct to airway clearance or as a method of overnight ventilation
or to increase functional exercise capacity. At the protocol stage and
when conducting short-term trials the power of the trial should be
considered. There is also a need to further establish the role of NIV
in exercise in CF and which subgroups would benefit most from
NIV intervention. Although it is impossible to double blind any
future trials, it is important to undertake blind assessment of the
participants to ensure good quality trials. Future trials should use
outcome measures which are considered important by people with
CF such as health-related quality of life and dyspnoea. Future trials
must also assess the impact ofNIV use on both people withCF and
their carers in terms of practical difficulties, such as inconvenience,
noise, intrusiveness and travel restrictions.
In the Young trial despite the benefits outlined above, nocturnal
hypoxaemia persisted in the NIV group and in the oxygen group.
Therfore further research is needed to establish if a combination
of NIV and oxygen is more effective in the long term.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dwyer 2015
Methods RCT.
Parallel design.
Duration: up to 2 weeks (during hospitalisation for an exacerbation)
Location: 2 hospital sites.
Participants 40 adults with CF and an acute exacerbation (defined as needing intravenous antibiotics
and four or more signs or symptoms from criteria by Fuchs (Fuchs 1994).
Moderate to severe disease FEV <60% predicted.
NIV group
Mean (SD) age: 28 (7) years.
Gender n (%): 6 (32) females.
BMI mean (SD): 21.4 (3.1) kg/m².
FVC mean (SD): 61 (15) % predicted.
PImax mean (SD): 87 (32) % predicted.
PEmax mean (SD): 70 (22) % predicted.
Control group
Mean (SD) age: 30 (9) years.
Gender n (%): 8 (38) females.
BMI mean (SD): 20.4 (3.0) kg/m².
FVC mean (SD): 63 (15) % predicted.
PImax mean (SD): 93 (30) % predicted.
PEmax mean (SD): 92 (41) % predicted.
Interventions Intervention (n = 19): versus standard airway clearance + NIV delivered by a nasal mask
or mouthpiece
Control: standard airway clearance.
NIV: mean (SD) IPAP 13 cm H 0 (2); mean (SD) EPAP: 5 cm H 0 (1)
Standard airway clearance = ACBT+ percussions; vibrations; postural drainage; some
other techniques were also used for some treatments
Outcomes Primary outcome measure: change in FEV % predicted from admission to discharge.
Secondary outcome measures: visual analogue score; modified shuttle walk test; short-
ness of breath; sputum volume; energy levels; PImax, PEmax; quality of life (CFQ);
quantitative sputum microbiology, length of admission; time to next hospital admission
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated block randomisa-
tion”.
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Dwyer 2015 (Continued)
Allocation concealment (selection bias) Low risk Randomisation schedule was “... stored in
sealed sequentially numbered opaque en-
velopes opened after consent signed”
Blinding (performance bias and detection
bias)
All outcomes
High risk It is not possible to blind participants or
assessors to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for. Three par-
ticipants withdrew from the study and the
data from these participants were used, as
available and appropriate, in the analyses of
daily rate of improvement, length of stay
and time to next hospital admission
Selective reporting (reporting bias) Low risk All the outcomes listed in the paper’s
methodology are the same as those pre-
sented in the results section of the full pa-
per
Other bias Low risk Methods of statistical analysis were de-
scribed.
Fauroux 1999
Methods RCT.
Cross-over design.
Duration: single session.
Participants 16 participants with CF. Stable participants.
Mean (SD) age 13 (4) years.
Interventions Session 1: CPT (10 to 15 forced expiration manoeuvres separated by rest periods) and
inspiratory PSV via nasal mask using pressure support generator.
Session 2: CPT with no PSV.
Sessions 20 minutes each but time between sessions unclear - paper states sessions were
conducted on 2 different days at the same time of day by same physiotherapist
Outcomes Lung function (FVC; FEV ; PEF; FEF25%; FEF50%; FEF25−75%), airway resistance,
SpO ; RR; PImax; PEmax; sputum weight; subjective participants impressions of fa-
tigue, ease sputum clearance; participant preference (1 = worse to 3 = marked preference)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Fauroux 1999 (Continued)
Random sequence generation (selection
bias)
Unclear risk States order of intervention was ran-
domised, but no details given
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants’ subjective impressions were
evaluated by individuals who were not in-
volved in the trial and were unaware of
the treatment regimen; but it was not re-
ported who was responsible for collecting
and weighing secretions and lung function
testing
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for.
Selective reporting (reporting bias) Low risk All outcome measures were reported.
Other bias Low risk Methods of statistical analysis were de-
scribed.
Gozal 1997
Methods RCT.
Cross-over design.
Duration: 3 nights within a 15-day period.
Participants Six participants with CF andmoderate to severe lung disease and significant gas exchange
abnormalities during sleep. Stable participants.
Age mean (SD) [range]: 22.3 (4.7) [13 - 28].
FEV % predicted mean (SD): 29.4% (3.4).
Interventions Session 1: room air.
Session 2: night-time bilevel NIPPV with supplemental oxygen given via nasal mask
Outcomes TST; sleep latency; NREM; NREM%TST; REM min; REM%TST; undetermined %
TST; total arousals; arousal index; SaO ; TcCO
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated as randomised, methods not dis-
cussed.
Allocation concealment (selection bias) Unclear risk Not discussed.
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Gozal 1997 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants were obviously aware of the in-
tervention being administered; however, all
were reportedly unaware of the purpose of
the trial with participants and sleep tech-
nicians blinded to the results until comple-
tion of the third night
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 participants dropped out due to non-tol-
erance of NIV; it was not explicitly stated
that intention-to-treat was not used, but re-
sults are based on the remaining 6 partici-
pants who completed the trial
Selective reporting (reporting bias) Low risk All outcome measures were reported.
Other bias Unclear risk Methods of statistical analysis were de-
scribed.
Holland 2003
Methods RCT (order of intervention was randomised on days 3 and 4 of hospital admission)
Cross-over design.
Duration: single intervention of each.
Participants 26 participants with CF and moderate to severe disease. Acute participants.
Mean (SD) age 27.04 (6.42) years.
Mean (SD) FEV % predicted 33.85 (11.85).
Interventions Session 1: CPT by ACBT i.e. (thoracic expansion x6, breathing control) x2, FET and
cough as required
Session 2: ACBTas above withNIV via nasal maskwith heated humidification entrained
NIV range: IPAP 10 - 12 cm H 0; EPAP 4 - 5 cm H 0.
Outcomes FVC; FEV ; FEF25−75; PImax; PEmax; SpO ; sputum weight; Borg breathlessness
score; participant preference
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States order of intervention was ran-
domised, but no details given
Allocation concealment (selection bias) Unclear risk Not discussed.
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Holland 2003 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk An independent data collector who was
blinded to the treatment order obtained all
measurements
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information provided about 1 drop out at
the start of testing
Selective reporting (reporting bias) Low risk All outcome measures were reported.
Other bias Unclear risk Methods of statistical analysis were de-
scribed.
Kofler 1998
Methods RCT.
Cross-over design.
Duration: single sessions on 2 successive days, time between 2 sessions is 1 day
Participants 20 participants with CF. No detail on whether participants are in acute or stable state,
but participants have mean (SD) Swachman-Kowalski score of 80.8 (15.3) indicating
that they have mild disease.
Mean (range) age 15.25 (6 - 23) years.
Interventions Session 1: PEP treatment (no details of PEP treatment).
Session 2: bilevel positive airway pressure (BiPaP) treatment, type of interface unclear
Outcomes FEV ; FVC; SaO ; FEF25−75; MEF50; FEF25−75; participant preference.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States order of intervention was ran-
domised, but no details given
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Data collection was not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for.
Selective reporting (reporting bias) Unclear risk Not clear whether all outcomes measured
were reported in this abstract
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Kofler 1998 (Continued)
Other bias Unclear risk Methods of statistical analysis were not de-
scribed.
Lima 2014
Methods RCT.
Cross-over design.
Duration: single session, each 24 to 48 hrs apart.
Participants 13 participants with CF. Mild, moderate and severe lung disease. Stable state with no
history of hospitalisation for respiratory failure in previous 3 months.
Mean age: 10.77 years.
Mean FEV % predicted: 62%.
Mean BMI: 33.78 kg/m².
Interventions Session 1: 6MWT with (type of interface unclear).
Session 2: 6MWT with no NIV.
6MWT speed 2.5 km/h and increased every 30 seconds up to a maximum of 7 km/h
NIV: IPAP 12 cm H 0; EPAP mean (SD) 6 (2) cm H 0.
Outcomes Walking distance, spirometry (FEV , FVC, FEF 25−75), OEP (TV, MV, Vprc, Vab),
RR, HR, SpO .
OEP and spirometry measured before and 5 min after test.
RR, HR and SpO measured immediately before, immediately after and 5 min after
test
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random permutated
blocks.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Open trial - no evidence so no blinding
of assessors, investigators or participants in
the published report
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for.
Selective reporting (reporting bias) Low risk Primary outcomes in protocol were re-
ported. Some indices of secondary out-
comes regarding rib cage volume P values
reported in the abstract, but not reported
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Lima 2014 (Continued)
within the full text i.e. VRCP, VRCA, and
VAB
Other bias Low risk Methods of statistical analysis were de-
scribed.
Milross 2001
Methods RCT.
Cross-over design.
Duration: 3 nights within a 1-week period, time between nights unclear
Participants 13 participants with CF with severe lung disease.
Mean (SD) age: 26 (5.9) years.
Mean (SD) FEV % predicted: 31.7% (10.6).
Awake PaO (range): 53 - 77 mmHg.
PaCO ≥ 45 mmHg.
BMI mean (SD): 20 (3) kg/m².
Interventions Session 1: room air and low-level CPAP (4 - 5 cm H O).
Session 2: oxygen (1.4 +/- 0.9L/min to maintain SaO ≥ 90%) and low-level CPAP (4
- 5 cm H O) via a nasal mask.
Session 3: BVS +/- oxygen (0.7+/-0.9 L/min to maintain SaO ≥ 90%).
Outcomes VI, VT; RR; respiratory disturbance indices; SaO TcCO .
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated as randomised, methods not dis-
cussed.
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
High risk No evidence of blinding of assessors, inves-
tigators or participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop outs.
Selective reporting (reporting bias) Low risk All outcome measures were reported.
Other bias Unclear risk Methods of statistical analysis were de-
scribed.
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Placidi 2006
Methods RCT.
Cross-over design.
Duration: treatment 2x daily for 70 min for 2 days per intervention
Participants 17 participants with CF. Severe lung disease. Acute participants.
Mean (SD) age: 27 (7) years.
FEV % predicted mean (SD): 25% (6).
BMI mean (SD): 18 (3) kg/m².
MIP % predicted mean (SD): 87% (17).
Wet weight sputum mean (SD): 5 (5) g.
Interventions Intervention 1: directed cough;
Intervention 2: PEP via nasal mask.
Intervention 3: CPAP via nasal mask;
Intervention for NIV with IPAP 8 - 12 cm H O; EPAP 4 cm H O.
Outcomes Sputumwet and dry weight; number spontaneous coughs; FEV ; FVC; FEF; mean SpO
; participants subjective impression of the effectiveness and fatigue induced by each
treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation of treatment order was
done according to the Latin square design
which provided a balanced assignment to
each treatment and a balance in the se-
quence of treatments
Allocation concealment (selection bias) Unclear risk Not discussed.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Physiotherapists collected sputum and the
technician was blinded to physiotherapy
treatment but it is not identified who was
responsible for weighing sputum or col-
lating cough information induced by the
treatment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All participants were accounted for.
Selective reporting (reporting bias) Low risk All outcome measures were reported.
Other bias Unclear risk Methods of statistical analysis were de-
scribed.
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Rodriguez Hortal 2016
Methods RCT.
Parallel design.
Duration: both interventions given 2x daily for 60 min for 3 months
Participants 32 participants with CF.
Mean (SD) age: 31 (10) years.
Moderate to severe lung disease.
Baseline FEV % predicted mean (SD) (range): 47% (14) (22% to 69%)
Baseline FVC % predicted mean (SD): 69% (13).%.
Interventions Intervention 1: treatment including bronchodilators; AD with HTS for 15 min; then
NIV with face mask; FET/huffing from mid to low lung volume.
Intervention 2: treatment including bronchodilators; AD with HTS for 15 min; then
PEP with mask; FET/huffing from mid to low lung volume
NIV: IPAP 20 cm H O minimum; EPAP 10 cm H O.
PEP: 10 breaths with 10 to 20 cm H O resistance.
Outcomes Lung function (FEV ; FVC; LCI), 6MWT, PaCO , sputum culture, inflammatory
blood markers
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States randomised but no further details
given.
Allocation concealment (selection bias) Low risk States opaque envelopes were used to assign
to 1 of 2 groups
Blinding (performance bias and detection
bias)
All outcomes
Low risk Pulmonary lab technicians blinded tophys-
iotherapy treatment took lung function
readings; research nurses blinded to treat-
ment took vital signs; 6MWT was per-
formed by the physiotherapist although it
is unclear if the physiotherapist conducting
the 6MWT is blinded to treatment alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for.
Selective reporting (reporting bias) Low risk It is stated that inflammatory blood mark-
ers, blood gases and sputum analysis
monthly was non-significant compared to
baseline (data not reported); FRC did not
change in either group (data not reported)
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Rodriguez Hortal 2016 (Continued)
All other outcome measures were reported.
Other bias Low risk Methods of statistical analysis were re-
ported.
Young 2008
Methods RCT.
Cross-over design.
Duration: each intervention for 6 weeks with 2-week washout period
Participants 8 participants with CF. Moderate and severe lung disease. No details on whether partic-
ipants are in acute or stable state.
Mean (SD) age: 37 (8) years.
Mean (SD) FEV % predicted: 35% (8).
Mean (SD) BM:I 21.1 (2.6) kg/m².
Mean (SD) PaCO : 52 (4) mmHg.
Interventions Intervention 1: nocturnal air (placebo).
Intervention 2: oxygen via nasal or full face mask.
Intervention 2: NIV via nasal or full face mask.
Outcomes CF-specific QoL questionnaire; daytime sleepiness; exertional dyspnoea; awake and
asleep gas exchange; sleep architecture; lung function; peak exercise capacity
Post-treatment assessments were carried out during a period of clinical stability i.e. no
current need for hospitalisation or intravenous antibiotics
Notes Alsomeasured neurocognitive function (PVT :mean; error; lapse); StroopColor&Word
test; trail-making test; controlled oral word association and digital span test which were
reported in the online supplement. They are not reported in this review as they were not
relevant to the aims of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated Latin square design.
Allocation concealment (selection bias) Low risk Sealed in sequentially numbered opaque
envelopes by a person not involved in the
trial and opened as each participant was en-
rolled
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants remained blinded as to
whether they were receiving oxygen or
room air only
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Young 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk One withdrawal after randomisation due
to a pneumothorax. One withdrawal from
NIV group due to mask discomfort (NIV
n = 7; O n = 8)
Selective reporting (reporting bias) Low risk All outcome measures were reported.
Other bias Low risk Methods of statistical analysis were de-
scribed.
Full abbreviations list can be found in “Additional Tables” (Table 1)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Elkins 2004 This trial did not compare NIV to increase minute ventilation and is not linked to the outcome measures in
this review
Falk 2006 This trial did not use NIV.
Fauroux 2000a This trial did not compare NIV with other management for acute or chronic respiratory failure
Fauroux 2000b This trial is not comparing NIV with other management strategies for acute or chronic respiratory failure
Fauroux 2001 This is not a randomised controlled trial of NIV versus no NIV
Fauroux 2004 This trial did not compare NIV with other management for acute or chronic respiratory failure
Greenough 2004 This trial did not use NIV.
Parreira 2008 This trial did not use NIV pressure or volume preset mode.
Piper 1992 This is not a randomised controlled trial.
Regnis 1994 This is not a randomised controlled trial.
Riethmueller 2006 This trial did not use NIV.
Serra 2000 This is not a randomised controlled trial of NIV versus no NIV
Serra 2002 This is not a randomised controlled trial of NIV versus no NIV
see Table 1
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Characteristics of studies awaiting assessment [ordered by study ID]
Petrone 2009
Methods Participants divided into 3 random groups.
Sleep studies performed on respiratory ward supervised by experienced nurses
Duration: 6 months treatment.
Participants 21 participants.
Mean (SD) age: 27.3 (3.7) years.
Mean (SD) FEV % predicted: 44.1% (3.10).
Interventions Group 1: ACBT.
Group 2: ACBT with oxygen.
Group 3: ACBT with NIV.
Outcomes Frequency of respiratory exacerbations; arterial blood gases; spirometry; SWT; sleep parameters: AHI; mean SaO
%; % of TST; oxygen desaturation index; SpO mean % of TST; TcCO mean of TST
Notes This is all the detail which is recorded in the abstract. To be completed once full study details are available
see Table 1
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D A T A A N D A N A L Y S E S
Comparison 1. NIV versus no NIV during chest physiotherapy (any technique)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CFQ scores 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Physical Domain 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Health Domain 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Respiratory Domain 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Fatigue 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 FEV1 (L) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Up to 1 week (directed
cough)
2 86 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.17, 0.12]
3.2 Up to 1 week (PEP) 1 34 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.22, 0.12]
4 FEV1 (% predicted) 3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Up to 1 week (directed
cough)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Up to 2 weeks (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Up to 3 months (PEP) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 FVC (L) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Up to 1 week (directed
cough)
2 86 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.30, 0.30]
5.2 Up to 1 week (PEP) 1 34 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.47, 0.33]
6 FVC (% predicted) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Up to 1 week (directed
cough)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Up to 3 months (PEP) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 FEF25-75 (L) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Up to 1 week (directed
cough)
2 86 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.08, 0.07]
7.2 Up to 1 week (PEP) 1 34 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.07, 0.07]
8 FEF25-75 (% predicted) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Up to 1 week (directed
cough)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Respiratory muscle strength
PImax (cmH20)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Up to 1 week (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Up to 2 weeks (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Respiratory muscle strength
PEmax (cmH20)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Up to 1 week (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Up to 2 weeks (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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11 Airway resistance % predicted 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Up to 1 week (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 LCI 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Up to 3 months (PEP) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Oxygen saturation during
airway clearance (%)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Up to 1 week (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Oxygen saturation during
airway clearance (change in
SpO2 % during treatment)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Up to 1 week (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Oxygen saturation after airway
clearance (SpO2)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 Up to 1 week (directed
cough)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Up to 1 week (PEP) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 PaCO2 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 Up to 3 months (PEP) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Breathlessness 2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
17.1 Up to 1 week (Borg
breathlessness score)
1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 Up to 2 weeks (VAS
score)
1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Sputum wet weight (g) 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 Up to 1 week (directed
cough)
3 118 Mean Difference (IV, Fixed, 95% CI) -0.69 [-3.06, 1.67]
18.2 Up to 1 week (PEP) 1 34 Mean Difference (IV, Fixed, 95% CI) -2.58 [-6.11, 0.95]
19 Sputum dry weight (g) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19.1 Up to 1 week (directed
cough)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.2 Up to 1 week (PEP) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Sputum volume per day (VAS
score)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 Up to 2 weeks (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Pseudomonas density (log
CFU/g)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
21.1 Up to 2 weeks (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Exercise capacity: 25 level
modified shuttle test (m)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 Up to 2 weeks (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Energy (VAS score) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
23.1 Up to 2 weeks (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
24 6MWT 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
24.1 Up to 3 months (PEP) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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25 Length of hospital stay (days) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
25.1 Up to 2 weeks (all
techniques combined)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26 Time to next admission (days) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. NIV in overnight ventilation compared to oxygen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CFQoL chest symptom score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 CFQoL transitional dyspnoea
index
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Symptoms of sleep-disordered
breathing
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Epworth Sleepiness Scale
(up to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Global PSQI (up to 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Lung function during sleep 1 Mean Difference (Fixed, 95% CI) Totals not selected
4.1 VI (L/m) while awake
(single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 VI (L/m) during REM
(single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 VI (L/m) during NREM
(single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 VT (L) while awake
(single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 VT (L) during REM
(single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 VT (L) during NREM
(single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Respiratory rate (breaths/min) 1 Mean Difference (Fixed, 95% CI) Totals not selected
5.1 RR while awake (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 RR during REM (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 RR during NREM (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Lung function while awake 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 FEV1% predicted (up to 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 FVC % predicted (up to 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Arterial blood gases: pH 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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8 Arterial blood gases: PaO2
(mmHg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Arterial blood gases: PaCO2
(mmHg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Arterial blood gases: HCO3
(mmol/L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Arterial blood gases: SaO2 (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Exercise performance (MSWT)
(metres)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Total sleep time (min) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Single night 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 REM sleep architecture 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 REM (single night) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 REM %TST (single
night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.3 REM % TST (up to 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Sleep latency (min) 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 Single night 2 38 Mean Difference (IV, Fixed, 95% CI) 2.93 [-0.32, 6.19]
15.2 Up to 3 months 1 15 Mean Difference (IV, Fixed, 95% CI) -5.0 [-19.17, 9.17]
16 Nocturnal oxygen saturation
(%)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 Mean SpO2 REM (single
night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 Mean SpO2 NREM
(single night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.3 Mean SpO2 for TST (up
to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.4 TST with SpO2 < 90%
(up to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Nocturnal oxygen saturation
(%)
1 Mean Difference (Fixed, 95% CI) Totals not selected
17.1 Percentage TST
SpO2>90%
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 Percentage REM
SpO2>90%
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
17.3 Percentage NREM
SpO2>90%
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Nocturnal TcCO2 (mmHg 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 TcCO2 during REM
(single night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 TcCO2 during NREM
(single night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.3 Mean change PtCO2
(mmHg) (up to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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18.4 Mean change PaCO2
(mmHg) (up to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Nocturnal TcCO2 (mmHg) 1 Mean Difference (Fixed, 95% CI) Totals not selected
19.1 Mean change TcCO2
NREM to REM (single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
19.2 Maximum TcCO2
(single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Nocturnal TcCO2 TST
(mmHg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 Mean PtCO2 TST (up
to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 Maximum PtCO2 TST
(up to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Hypopneas 1 Relative rate (Fixed, 95% CI) Totals not selected
21.1 Single night 1 Relative rate (Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Mean heart rate (beats/min) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Respiratory rate 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
23.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. NIV in overnight ventilation compared to room air
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CF QoL chest symptom score 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 CF QoL traditional dyspnoea
index score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Symptoms of sleep-disordered
breathing
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Epworth sleepiness scale
(up to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Global PSQI (up to 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Lung function during sleep 1 Mean Difference (Fixed, 95% CI) Totals not selected
4.1 VI while awake (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 VI during REM (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 VI during NREM (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 VT while awake (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 VT during REM (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.6 VT during NREM (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
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5 Respiratory rate(breaths/min)
during sleep
1 Mean Difference (Fixed, 95% CI) Totals not selected
5.1 RR while awake (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 RR during REM (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 RR during NREM (single
night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Mean Respiratory Rate 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Mean Heart Rate (beats/min) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Lung function while awake 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 FEV1% predicted (up to 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 FVC % predicted (up to 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Arterial blood gases: pH 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Arterial blood gases: PaO2
(mmHg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Arterial blood gases: PaCO2
(mmHg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Arterial blood gases: HCO3
(mmol/L)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Arterial blood gases: SaO2 (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Exercise performance (metres) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Total sleep time (min) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 Single night 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 REM sleep architecture 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 REM (single night) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 REM %TST (single
night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.3 REM % TST (up to 3
months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Sleep latency 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Single night 2 38 Mean Difference (IV, Fixed, 95% CI) -2.63 [-7.37, 2.11]
17.2 At 6 weeks 1 15 Mean Difference (IV, Fixed, 95% CI) -3.00 [-19.88, 13.
88]
18 Nocturnal oxygen saturation
(%)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
18.1 Mean SpO2 REM (single
night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 Mean SpO2 NREM
(single night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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18.3 Mean SpO2 for TST (up
to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.4 TST for SpO2 < 90%
(up to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Nocturnal oxygen saturation
(%)
1 Mean Difference (Fixed, 95% CI) Totals not selected
19.1 Percentage TST SpO2 >
90% (single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
19.2 Percentage REM SpO2 >
90% (single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
19.3 Percentage NREM SpO2
> 90% (single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Nocturnal TcCO2 (mmHg) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 TcCO2 during REM
(single night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 TcCO2 during NREM
(single night)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.3 Mean change PtCO2 (up
to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.4 Mean change PaCO2 (up
to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Nocturnal TcCO2(mmHg) 1 Mean Difference (Fixed, 95% CI) Totals not selected
21.1 Mean change TcCO2
NREM to REM (single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
21.2 Maximum TcCO2
(single night)
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Nocturnal TcCO2 TST
(mmHg)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 Mean PtCO2 TST (up
to 3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.2 Max PtCO2 TST (up to
3 months)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Hypopneas 1 Relative rate (Fixed, 95% CI) Totals not selected
23.1 Single night 1 Relative rate (Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. NIV versus no NIV during exercise testing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 6 minute walk test 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Up to 1 week 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 1
CFQ scores.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 1 CFQ scores
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Physical Domain
Dwyer 2015 17 54 (27) 20 58 (22) -4.00 [ -20.05, 12.05 ]
2 Health Domain
Dwyer 2015 17 59 (24) 20 56 (24) 3.00 [ -12.52, 18.52 ]
3 Respiratory Domain
Dwyer 2015 17 62 (17) 20 51 (15) 11.00 [ 0.58, 21.42 ]
-20 -10 0 10 20
Favours chest physio Favours NIV
Analysis 1.2. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 2
Fatigue.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 2 Fatigue
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dwyer 2015 17 37 (13.4) 20 43 (8) -6.00 [ -13.27, 1.27 ]
-20 -10 0 10 20
Favours NIV Favours chest physio
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Analysis 1.3. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 3
FEV1 (L).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 3 FEV1 (L)
Study or subgroup NIV Chest physiotherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Holland 2003 26 1.35 (0.44) 26 1.35 (0.48) 34.6 % 0.0 [ -0.25, 0.25 ]
Placidi 2006 17 0.95 (0.25) 17 0.99 (0.29) 65.4 % -0.04 [ -0.22, 0.14 ]
Subtotal (95% CI) 43 43 100.0 % -0.03 [ -0.17, 0.12 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
2 Up to 1 week (PEP)
Placidi 2006 17 0.95 (0.25) 17 1 (0.27) 100.0 % -0.05 [ -0.22, 0.12 ]
Subtotal (95% CI) 17 17 100.0 % -0.05 [ -0.22, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours chest physio Favours NIV
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Analysis 1.4. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 4
FEV1 (% predicted).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 4 FEV1 (% predicted)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Fauroux 1999 16 50.4 (22.8) 16 51.3 (24.8) -0.90 [ -17.41, 15.61 ]
2 Up to 2 weeks (all techniques combined)
Dwyer 2015 17 49.5 (14.3) 20 48.2 (12.1) 1.30 [ -7.32, 9.92 ]
3 Up to 3 months (PEP)
Rodriguez Hortal 2016 16 41 (12) 16 54 (12) -13.00 [ -21.32, -4.68 ]
-20 -10 0 10 20
Favours chest physio Favours NIV
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Analysis 1.5. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 5
FVC (L).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 5 FVC (L)
Study or subgroup NIV Chest physiotherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Holland 2003 26 2.55 (0.75) 26 2.51 (0.98) 39.9 % 0.04 [ -0.43, 0.51 ]
Placidi 2006 17 1.93 (0.57) 17 1.95 (0.58) 60.1 % -0.02 [ -0.41, 0.37 ]
Subtotal (95% CI) 43 43 100.0 % 0.00 [ -0.30, 0.30 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
2 Up to 1 week (PEP)
Placidi 2006 17 1.93 (0.57) 17 2 (0.62) 100.0 % -0.07 [ -0.47, 0.33 ]
Subtotal (95% CI) 17 17 100.0 % -0.07 [ -0.47, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours chest physio Favours NIV
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Analysis 1.6. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 6
FVC (% predicted).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 6 FVC (% predicted)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Fauroux 1999 16 61.1 (20) 16 60.7 (20) 0.40 [ -13.46, 14.26 ]
2 Up to 3 months (PEP)
Rodriguez Hortal 2016 16 61 (16) 16 78 (12) -17.00 [ -26.80, -7.20 ]
-20 -10 0 10 20
Favours chest physio Favours NIV
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Analysis 1.7. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 7
FEF25-75 (L).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 7 FEF25−75 (L)
Study or subgroup NIV Chest physiotherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Holland 2003 26 0.57 (0.33) 26 0.53 (0.42) 12.4 % 0.04 [ -0.17, 0.25 ]
Placidi 2006 17 0.27 (0.11) 17 0.28 (0.12) 87.6 % -0.01 [ -0.09, 0.07 ]
Subtotal (95% CI) 43 43 100.0 % 0.00 [ -0.08, 0.07 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Up to 1 week (PEP)
Placidi 2006 17 0.27 (0.11) 17 0.27 (0.11) 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 17 17 100.0 % 0.0 [ -0.07, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours chest physio Favours NIV
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Analysis 1.8. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 8
FEF25-75 (% predicted).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 8 FEF25−75 (% predicted)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Fauroux 1999 16 42.1 (26.4) 16 48.1 (36.4) -6.00 [ -28.03, 16.03 ]
-100 -50 0 50 100
Favours chest physio Favours NIV
Analysis 1.9. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 9
Respiratory muscle strength PImax (cmH20).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 9 Respiratory muscle strength PImax (cmH20)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (all techniques combined)
Fauroux 1999 16 83.9 (8.7) 16 60.9 (5.3) 23.00 [ 18.01, 27.99 ]
2 Up to 2 weeks (all techniques combined)
Dwyer 2015 17 97 (37) 20 105 (34) -8.00 [ -31.05, 15.05 ]
-20 -10 0 10 20
Favours chest physio Favours NIV
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Analysis 1.10. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 10
Respiratory muscle strength PEmax (cmH20).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 10 Respiratory muscle strength PEmax (cmH20)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (all techniques combined)
Fauroux 1999 16 88 (7.4) 16 77.5 (4.8) 10.50 [ 6.18, 14.82 ]
2 Up to 2 weeks (all techniques combined)
Dwyer 2015 17 108 (37) 20 128 (48) -20.00 [ -47.42, 7.42 ]
-50 -25 0 25 50
Favours chest physio Favours NIV
Analysis 1.11. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 11
Airway resistance % predicted.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 11 Airway resistance % predicted
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (all techniques combined)
Fauroux 1999 16 159 (28) 16 168 (36) -9.00 [ -31.35, 13.35 ]
-50 -25 0 25 50
Favours NIV Favours chest physio
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Analysis 1.12. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 12
LCI.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 12 LCI
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months (PEP)
Rodriguez Hortal 2016 16 9.2 (2.55) 16 9.76 (2.5) -0.56 [ -2.31, 1.19 ]
-20 -10 0 10 20
Favours chest physio Favours NIV
Analysis 1.13. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 13
Oxygen saturation during airway clearance (%).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 13 Oxygen saturation during airway clearance (%)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N
Mean(SD)[*SpO2
mean] N
Mean(SD)[*SpO2
mean] IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (all techniques combined)
Fauroux 1999 16 -0.2 (0.8) 16 -1.2 (1.2) 1.00 [ 0.29, 1.71 ]
-2 -1 0 1 2
Favours chest physio Favours NIV
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Analysis 1.14. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 14
Oxygen saturation during airway clearance (change in SpO2 % during treatment).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 14 Oxygen saturation during airway clearance (change in SpO2 % during treatment)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (all techniques combined)
Kofler 1998 20 1.2 (2.1) 20 0.04 (1.28) 1.16 [ 0.08, 2.24 ]
-2 -1 0 1 2
Favours Chest Physio Favours NIV
Analysis 1.15. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 15
Oxygen saturation after airway clearance (SpO2).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 15 Oxygen saturation after airway clearance (SpO2)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Placidi 2006 17 94.8 (1.4) 17 94.6 (1.4) 0.20 [ -0.74, 1.14 ]
2 Up to 1 week (PEP)
Placidi 2006 17 94.8 (1.4) 17 94.9 (1.2) -0.10 [ -0.98, 0.78 ]
-1 -0.5 0 0.5 1
Favours chest physio Favours NIV
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Analysis 1.16. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 16
PaCO2.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 16 PaCO2
Study or subgroup NIV PEP
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months (PEP)
Rodriguez Hortal 2016 16 5.14 (0.66) 16 5.12 (0.53) 0.02 [ -0.39, 0.43 ]
-1 -0.5 0 0.5 1
Favours NIV Favours PEP
Analysis 1.17. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 17
Breathlessness.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 17 Breathlessness
Study or subgroup NIV Chest physiotherapy
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (Borg breathlessness score)
Holland 2003 26 2.26 (1.96) 26 2.69 (1.82) -0.22 [ -0.77, 0.32 ]
2 Up to 2 weeks (VAS score)
Dwyer 2015 17 1.9 (1.3) 20 2.1 (2) -0.11 [ -0.76, 0.53 ]
-2 -1 0 1 2
Favours NIV Favours chest physio
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Analysis 1.18. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 18
Sputum wet weight (g).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 18 Sputum wet weight (g)
Study or subgroup NIV Chest physiotherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Fauroux 1999 16 4.6 (19.2) 16 5.3 (21.2) 2.8 % -0.70 [ -14.71, 13.31 ]
Holland 2003 26 15.32 (6.2) 26 15.92 (6.44) 47.3 % -0.60 [ -4.04, 2.84 ]
Placidi 2006 17 13.2 (5) 17 13.98 (4.96) 49.8 % -0.78 [ -4.13, 2.57 ]
Subtotal (95% CI) 59 59 100.0 % -0.69 [ -3.06, 1.67 ]
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Up to 1 week (PEP)
Placidi 2006 17 13.2 (5) 17 15.78 (5.49) 100.0 % -2.58 [ -6.11, 0.95 ]
Subtotal (95% CI) 17 17 100.0 % -2.58 [ -6.11, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
-10 -5 0 5 10
Favours chest physio Favours NIV
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Analysis 1.19. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 19
Sputum dry weight (g).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 19 Sputum dry weight (g)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week (directed cough)
Placidi 2006 17 0.88 (0.62) 17 0.97 (0.76) -0.09 [ -0.56, 0.38 ]
2 Up to 1 week (PEP)
Placidi 2006 17 0.88 (0.62) 17 0.94 (0.57) -0.06 [ -0.46, 0.34 ]
-1 -0.5 0 0.5 1
Favours chest physio Favours NIV
Analysis 1.20. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 20
Sputum volume per day (VAS score).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 20 Sputum volume per day (VAS score)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 2 weeks (all techniques combined)
Dwyer 2015 17 2 (1.4) 20 2.5 (2.2) -0.50 [ -1.67, 0.67 ]
-4 -2 0 2 4
Favours chest physio Favours NIV
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Analysis 1.21. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 21
Pseudomonas density (log CFU/g).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 21 Pseudomonas density (log CFU/g)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 2 weeks (all techniques combined)
Dwyer 2015 14 6.77 (1.68) 18 7.71 (0.85) -0.94 [ -1.90, 0.02 ]
-2 -1 0 1 2
Favours NIV Favours chest physio
Analysis 1.22. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 22
Exercise capacity: 25 level modified shuttle test (m).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 22 Exercise capacity: 25 level modified shuttle test (m)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 2 weeks (all techniques combined)
Dwyer 2015 17 914 (343) 20 929 (418) -15.00 [ -260.24, 230.24 ]
-200 -100 0 100 200
Favours chest physio Favours NIV
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Analysis 1.23. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 23
Energy (VAS score).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 23 Energy (VAS score)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 2 weeks (all techniques combined)
Dwyer 2015 17 3.2 (1.7) 20 3.2 (2.1) 0.0 [ -1.22, 1.22 ]
-2 -1 0 1 2
Favours chest physio Favours [NIV
Analysis 1.24. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 24
6MWT.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 24 6MWT
Study or subgroup NIV
Chest physio-
therapy
(PEP)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months (PEP)
Rodriguez Hortal 2016 16 559 (95) 16 553 (77) 6.00 [ -53.92, 65.92 ]
-100 -50 0 50 100
Favours NIV Favours PEP
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Analysis 1.25. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 25
Length of hospital stay (days).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 25 Length of hospital stay (days)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 2 weeks (all techniques combined)
Dwyer 2015 17 14.2 (4) 20 14.7 (3.9) -0.50 [ -3.06, 2.06 ]
-4 -2 0 2 4
Favours NIV Favours chest physio
Analysis 1.26. Comparison 1 NIV versus no NIV during chest physiotherapy (any technique), Outcome 26
Time to next admission (days).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 1 NIV versus no NIV during chest physiotherapy (any technique)
Outcome: 26 Time to next admission (days)
Study or subgroup NIV Chest physiotherapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dwyer 2015 17 245 (174) 20 219 (171) 26.00 [ -85.61, 137.61 ]
-200 -100 0 100 200
Favours chest physio Favours NIV
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Analysis 2.1. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 1 CFQoL chest
symptom score.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 1 CFQoL chest symptom score
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 71 (17) 8 68 (20) 3.00 [ -15.73, 21.73 ]
-20 -10 0 10 20
Favours oxygen Favours NIV
Analysis 2.2. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 2 CFQoL
transitional dyspnoea index.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 2 CFQoL transitional dyspnoea index
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 1 (1.8) 8 -0.4 (1.5) 1.40 [ -0.29, 3.09 ]
-4 -2 0 2 4
Favours oxygen Favours NIV
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Analysis 2.3. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 3 Symptoms of
sleep-disordered breathing.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 3 Symptoms of sleep-disordered breathing
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Epworth Sleepiness Scale (up to 3 months)
Young 2008 7 7 (5) 8 7 (6) 0.0 [ -5.57, 5.57 ]
2 Global PSQI (up to 3 months)
Young 2008 7 6 (3) 8 6 (2) 0.0 [ -2.62, 2.62 ]
-10 -5 0 5 10
Favours NIV Favours oxygen
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Analysis 2.4. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 4 Lung function
during sleep.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 4 Lung function during sleep
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 VI (L/m) while awake (single night)
Milross 2001 0.49 (0.47) 0.49 [ -0.43, 1.41 ]
2 VI (L/m) during REM (single night)
Milross 2001 1.48 (0.38) 1.48 [ 0.74, 2.22 ]
3 VI (L/m) during NREM (single night)
Milross 2001 0.49 (0.4) 0.49 [ -0.29, 1.27 ]
4 VT (L) while awake (single night)
Milross 2001 0.03 (0.03) 0.03 [ -0.03, 0.09 ]
5 VT (L) during REM (single night)
Milross 2001 0.08 (0.02) 0.08 [ 0.04, 0.12 ]
6 VT (L) during NREM (single night)
Milross 2001 0.03 (0.01) 0.03 [ 0.01, 0.05 ]
-2 -1 0 1 2
Favours oxygen Favours NIV
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Analysis 2.5. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 5 Respiratory rate
(breaths/min).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 5 Respiratory rate (breaths/min)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 RR while awake (single night)
Milross 2001 -0.33 (1.53) -0.33 [ -3.33, 2.67 ]
2 RR during REM (single night)
Milross 2001 -1.84 (0.72) -1.84 [ -3.25, -0.43 ]
3 RR during NREM (single night)
Milross 2001 -1.15 (0.68) -1.15 [ -2.48, 0.18 ]
-4 -2 0 2 4
Favours NIV Favours oxygen
Analysis 2.6. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 6 Lung function
while awake.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 6 Lung function while awake
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 FEV1% predicted (up to 3 months)
Young 2008 7 33 (9) 8 32 (9) 1.00 [ -8.13, 10.13 ]
2 FVC % predicted (up to 3 months)
Young 2008 7 58 (15) 8 54 (15) 4.00 [ -11.22, 19.22 ]
-20 -10 0 10 20
Favours oxygen Favours NIV
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Analysis 2.7. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 7 Arterial blood
gases: pH.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 7 Arterial blood gases: pH
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 7.39 (0.03) 8 7.39 (0.02) 0.0 [ -0.03, 0.03 ]
-0.05 -0.03 0 0.03 0.05
Favours oxygen Favours NIV
Analysis 2.8. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 8 Arterial blood
gases: PaO2 (mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 8 Arterial blood gases: PaO2 (mmHg)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 62 (6) 8 66 (12) -4.00 [ -13.43, 5.43 ]
-20 -10 0 10 20
Favours oxygen Favours NIV
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Analysis 2.9. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 9 Arterial blood
gases: PaCO2 (mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 9 Arterial blood gases: PaCO2 (mmHg)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 50 (5) 8 51 (7) -1.00 [ -7.10, 5.10 ]
-10 -5 0 5 10
Favours NIV Favours oxygen
Analysis 2.10. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 10 Arterial blood
gases: HCO3 (mmol/L).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 10 Arterial blood gases: HCO3 (mmol/L)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 30 (2) 8 30 (4) 0.0 [ -3.14, 3.14 ]
-4 -2 0 2 4
Favours oxygen Favours NIV
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Analysis 2.11. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 11 Arterial blood
gases: SaO2 (%).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 11 Arterial blood gases: SaO2 (%)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 92 (4) 8 94 (4) -2.00 [ -6.06, 2.06 ]
-10 -5 0 5 10
Favours oxygen Favours NIV
Analysis 2.12. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 12 Exercise
performance (MSWT) (metres).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 12 Exercise performance (MSWT) (metres)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 459 (144) 8 403 (114) 56.00 [ -76.74, 188.74 ]
-200 -100 0 100 200
Favours oxygen Favours NIV
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Analysis 2.13. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 13 Total sleep
time (min).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 13 Total sleep time (min)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Single night
Gozal 1997 6 390 (29) 6 386 (30) 4.00 [ -29.39, 37.39 ]
2 Up to 3 months
Young 2008 7 306 (26) 8 328 (39) -22.00 [ -55.19, 11.19 ]
-50 -25 0 25 50
Favours oxygen Favours NIV
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Analysis 2.14. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 14 REM sleep
architecture.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 14 REM sleep architecture
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 REM (single night)
Gozal 1997 6 57 (23) 6 70 (30) -13.00 [ -43.25, 17.25 ]
2 REM %TST (single night)
Gozal 1997 6 15 (5) 6 18 (7) -3.00 [ -9.88, 3.88 ]
3 REM % TST (up to 3 months)
Young 2008 7 22 (7) 8 20 (7) 2.00 [ -5.10, 9.10 ]
-50 -25 0 25 50
Favours oxygen Favours NIV
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Analysis 2.15. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 15 Sleep latency
(min).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 15 Sleep latency (min)
Study or subgroup NIV Oxygen
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Single night
Gozal 1997 6 23 (4) 6 18 (2) 82.8 % 5.00 [ 1.42, 8.58 ]
Milross 2001 13 6 (8) 13 13 (12) 17.2 % -7.00 [ -14.84, 0.84 ]
Subtotal (95% CI) 19 19 100.0 % 2.93 [ -0.32, 6.19 ]
Heterogeneity: Chi2 = 7.45, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 1.76 (P = 0.078)
2 Up to 3 months
Young 2008 7 13 (13) 8 18 (15) 100.0 % -5.00 [ -19.17, 9.17 ]
Subtotal (95% CI) 7 8 100.0 % -5.00 [ -19.17, 9.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 2.16. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 16 Nocturnal
oxygen saturation (%).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 16 Nocturnal oxygen saturation (%)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean SpO2 REM (single night)
Gozal 1997 6 88 (3) 6 90 (2) -2.00 [ -4.88, 0.88 ]
2 Mean SpO2 NREM (single night)
Gozal 1997 6 93 (2) 6 94 (1) -1.00 [ -2.79, 0.79 ]
3 Mean SpO2 for TST (up to 3 months)
Young 2008 7 92 (3) 8 93 (2) -1.00 [ -3.62, 1.62 ]
4 TST with SpO2 < 90% (up to 3 months)
Young 2008 7 23 (34) 8 10 (9) 13.00 [ -12.95, 38.95 ]
-50 -25 0 25 50
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Analysis 2.17. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 17 Nocturnal
oxygen saturation (%).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 17 Nocturnal oxygen saturation (%)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Percentage TST SpO2>90%
Milross 2001 -2.5446 (3.594) -2.54 [ -9.59, 4.50 ]
2 Percentage REM SpO2>90%
Milross 2001 0.6531 (4.896) 0.65 [ -8.94, 10.25 ]
3 Percentage NREM SpO2>90%
Milross 2001 -0.843 (3.6263) -0.84 [ -7.95, 6.26 ]
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Analysis 2.18. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 18 Nocturnal
TcCO2 (mmHg.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 18 Nocturnal TcCO2 (mmHg
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 TcCO2 during REM (single night)
Gozal 1997 6 6 (0.4) 6 7.9 (0.7) -1.90 [ -2.55, -1.25 ]
2 TcCO2 during NREM (single night)
Gozal 1997 6 5.7 (0.4) 6 7.1 (0.9) -1.40 [ -2.19, -0.61 ]
3 Mean change PtCO2 (mmHg) (up to 3 months)
Young 2008 7 2.7 (1.5) 8 5.5 (3.6) -2.80 [ -5.53, -0.07 ]
4 Mean change PaCO2 (mmHg) (up to 3 months)
Young 2008 7 -1.3 (4.1) 8 6 (4.2) -7.30 [ -11.51, -3.09 ]
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Analysis 2.19. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 19 Nocturnal
TcCO2 (mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 19 Nocturnal TcCO2 (mmHg)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean change TcCO2 NREM to REM (single night)
Milross 2001 -2.6025 (0.7373) -2.60 [ -4.05, -1.16 ]
2 Maximum TcCO2 (single night)
Milross 2001 -2.083 (4.367) -2.08 [ -10.64, 6.48 ]
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Analysis 2.20. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 20 Nocturnal
TcCO2 TST (mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 20 Nocturnal TcCO2 TST (mmHg)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean PtCO2 TST (up to 3 months)
Young 2008 7 53 (6) 8 62 (10) -9.00 [ -17.23, -0.77 ]
2 Maximum PtCO2 TST (up to 3 months)
Young 2008 7 58 (7) 8 72 (11) -14.00 [ -23.22, -4.78 ]
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Analysis 2.21. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 21 Hypopneas.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 21 Hypopneas
Study or subgroup log [Relative rate] Relative rate Relative rate
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Single night
Milross 2001 -3.881 (0.5052) 0.02 [ 0.01, 0.06 ]
0.005 0.1 1 10 200
Favours NIV Favours oxygen
Analysis 2.22. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 22 Mean heart
rate (beats/min).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 22 Mean heart rate (beats/min)
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 64 (15) 8 70 (18) -6.00 [ -22.70, 10.70 ]
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Analysis 2.23. Comparison 2 NIV in overnight ventilation compared to oxygen, Outcome 23 Respiratory
rate.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 2 NIV in overnight ventilation compared to oxygen
Outcome: 23 Respiratory rate
Study or subgroup NIV Oxygen
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 8 23 (5) 8 22 (3) 1.00 [ -3.04, 5.04 ]
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Analysis 3.1. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 1 CF QoL chest
symptom score.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 1 CF QoL chest symptom score
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 71 (17) 8 64 (20) 7.00 [ -11.73, 25.73 ]
-50 -25 0 25 50
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Analysis 3.2. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 2 CF QoL
traditional dyspnoea index score.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 2 CF QoL traditional dyspnoea index score
Study or subgroup NIV Room Air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 1 (1.8) 8 -1.9 (2.5) 2.90 [ 0.71, 5.09 ]
-4 -2 0 2 4
Favours Room Air Favours NIV
Analysis 3.3. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 3 Symptoms of
sleep-disordered breathing.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 3 Symptoms of sleep-disordered breathing
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Epworth sleepiness scale (up to 3 months)
Young 2008 7 7 (5) 8 7 (5) 0.0 [ -5.07, 5.07 ]
2 Global PSQI (up to 3 months)
Young 2008 7 6 (3) 8 7 (3) -1.00 [ -4.04, 2.04 ]
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Analysis 3.4. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 4 Lung function
during sleep.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 4 Lung function during sleep
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 VI while awake (single night)
Milross 2001 0.8756 (0.55) 0.88 [ -0.20, 1.95 ]
2 VI during REM (single night)
Milross 2001 1.56 (0.77) 1.56 [ 0.05, 3.07 ]
3 VI during NREM (single night)
Milross 2001 1.04 (0.34) 1.04 [ 0.37, 1.71 ]
4 VT while awake (single night)
Milross 2001 0.06 (0.03) 0.06 [ 0.00, 0.12 ]
5 VT during REM (single night)
Milross 2001 0.1 (0.03) 0.10 [ 0.04, 0.16 ]
6 VT during NREM (single night)
Milross 2001 0.05 (0.03) 0.05 [ -0.01, 0.11 ]
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Analysis 3.5. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 5 Respiratory
rate(breaths/min) during sleep.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 5 Respiratory rate(breaths/min) during sleep
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 RR while awake (single night)
Milross 2001 -0.71 (1.4) -0.71 [ -3.45, 2.03 ]
2 RR during REM (single night)
Milross 2001 -2.64 (0.54) -2.64 [ -3.70, -1.58 ]
3 RR during NREM (single night)
Milross 2001 -0.83 (1.18) -0.83 [ -3.14, 1.48 ]
-10 -5 0 5 10
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Analysis 3.6. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 6 Mean
Respiratory Rate.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 6 Mean Respiratory Rate
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 23 (5) 8 23 (5) 0.0 [ -5.07, 5.07 ]
-10 -5 0 5 10
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Analysis 3.7. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 7 Mean Heart
Rate (beats/min).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 7 Mean Heart Rate (beats/min)
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 8 64 (15) 8 73 (11) -9.00 [ -21.89, 3.89 ]
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Analysis 3.8. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 8 Lung function
while awake.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 8 Lung function while awake
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 FEV1% predicted (up to 3 months)
Young 2008 7 33 (9) 8 32 (10) 1.00 [ -8.62, 10.62 ]
2 FVC % predicted (up to 3 months)
Young 2008 7 58 (15) 8 54 (13) 4.00 [ -10.30, 18.30 ]
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Analysis 3.9. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 9 Arterial blood
gases: pH.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 9 Arterial blood gases: pH
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 7.39 (0.03) 8 7.38 (0.03) 0.01 [ -0.02, 0.04 ]
-0.05 -0.03 0 0.03 0.05
Favours Room Air Favours NIV
Analysis 3.10. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 10 Arterial
blood gases: PaO2 (mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 10 Arterial blood gases: PaO2 (mmHg)
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 62 (6) 8 64 (7) -2.00 [ -8.58, 4.58 ]
-10 -5 0 5 10
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Analysis 3.11. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 11 Arterial
blood gases: PaCO2 (mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 11 Arterial blood gases: PaCO2 (mmHg)
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 50 (5) 8 52 (7) -2.00 [ -8.10, 4.10 ]
-10 -5 0 5 10
Favours NIV Favours Room Air
Analysis 3.12. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 12 Arterial
blood gases: HCO3 (mmol/L).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 12 Arterial blood gases: HCO3 (mmol/L)
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 30 (2) 8 30 (3) 0.0 [ -2.55, 2.55 ]
-4 -2 0 2 4
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Analysis 3.13. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 13 Arterial
blood gases: SaO2 (%).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 13 Arterial blood gases: SaO2 (%)
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 92 (4) 8 93 (3) -1.00 [ -4.62, 2.62 ]
-4 -2 0 2 4
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Analysis 3.14. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 14 Exercise
performance (metres).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 14 Exercise performance (metres)
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 3 months
Young 2008 7 459 (144) 8 381 (132) 78.00 [ -62.52, 218.52 ]
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Analysis 3.15. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 15 Total sleep
time (min).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 15 Total sleep time (min)
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Single night
Gozal 1997 6 390 (29) 6 378 (49) 12.00 [ -33.56, 57.56 ]
2 Up to 3 months
Young 2008 7 306 (26) 8 331 (58) -25.00 [ -69.57, 19.57 ]
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Analysis 3.16. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 16 REM sleep
architecture.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 16 REM sleep architecture
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 REM (single night)
Gozal 1997 6 57 (23) 6 47 (18) 10.00 [ -13.37, 33.37 ]
2 REM %TST (single night)
Gozal 1997 6 15 (5) 6 12 (3) 3.00 [ -1.67, 7.67 ]
3 REM % TST (up to 3 months)
Young 2008 7 22 (7) 8 20 (8) 2.00 [ -5.59, 9.59 ]
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Analysis 3.17. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 17 Sleep latency.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 17 Sleep latency
Study or subgroup NIV Room air
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Single night
Gozal 1997 6 23 (4) 6 24 (6) 67.4 % -1.00 [ -6.77, 4.77 ]
Milross 2001 13 6 (8) 13 12 (13) 32.6 % -6.00 [ -14.30, 2.30 ]
Subtotal (95% CI) 19 19 100.0 % -2.63 [ -7.37, 2.11 ]
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
2 At 6 weeks
Young 2008 7 13 (13) 8 16 (20) 100.0 % -3.00 [ -19.88, 13.88 ]
Subtotal (95% CI) 7 8 100.0 % -3.00 [ -19.88, 13.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
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Analysis 3.18. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 18 Nocturnal
oxygen saturation (%).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 18 Nocturnal oxygen saturation (%)
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean SpO2 REM (single night)
Gozal 1997 6 88 (3) 6 79 (7) 9.00 [ 2.91, 15.09 ]
2 Mean SpO2 NREM (single night)
Gozal 1997 6 93 (2) 6 88 (5) 5.00 [ 0.69, 9.31 ]
3 Mean SpO2 for TST (up to 3 months)
Young 2008 8 92 (3) 8 89 (5) 3.00 [ -1.04, 7.04 ]
4 TST for SpO2 < 90% (up to 3 months)
Young 2008 8 23 (34) 8 48 (50) -25.00 [ -66.90, 16.90 ]
-50 -25 0 25 50
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Analysis 3.19. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 19 Nocturnal
oxygen saturation (%).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 19 Nocturnal oxygen saturation (%)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Percentage TST SpO2 > 90% (single night)
Milross 2001 27.58 (10.076) 27.58 [ 7.83, 47.33 ]
2 Percentage REM SpO2 > 90% (single night)
Milross 2001 34.527 (9.965) 34.53 [ 15.00, 54.06 ]
3 Percentage NREM SpO2 > 90% (single night)
Milross 2001 26.2054 (10.1891) 26.21 [ 6.24, 46.18 ]
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Analysis 3.20. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 20 Nocturnal
TcCO2 (mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 20 Nocturnal TcCO2 (mmHg)
Study or subgroup NIV Room air
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 TcCO2 during REM (single night)
Gozal 1997 6 6 (0.4) 6 6.9 (0.8) -0.90 [ -1.62, -0.18 ]
2 TcCO2 during NREM (single night)
Gozal 1997 6 5.7 (0.4) 6 6.4 (0.4) -0.70 [ -1.15, -0.25 ]
3 Mean change PtCO2 (up to 3 months)
Young 2008 7 2.7 (1.5) 8 4.9 (2.6) -2.20 [ -4.32, -0.08 ]
4 Mean change PaCO2 (up to 3 months)
Young 2008 7 -1.3 (4.1) 8 2 (2.3) -3.30 [ -6.73, 0.13 ]
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Analysis 3.21. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 21 Nocturnal
TcCO2(mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 21 Nocturnal TcCO2 (mmHg)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean change TcCO2 NREM to REM (single night)
Milross 2001 -2.308 (0.505) -2.31 [ -3.30, -1.32 ]
2 Maximum TcCO2 (single night)
Milross 2001 -0.7333 (5.1165) -0.73 [ -10.76, 9.29 ]
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Analysis 3.22. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 22 Nocturnal
TcCO2 TST (mmHg).
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 22 Nocturnal TcCO2 TST (mmHg)
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean PtCO2 TST (up to 3 months)
Young 2008 7 53 (6) 8 62 (13) -9.00 [ -19.05, 1.05 ]
2 Max PtCO2 TST (up to 3 months)
Young 2008 7 58 (7) 8 74 (19) -16.00 [ -30.15, -1.85 ]
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Analysis 3.23. Comparison 3 NIV in overnight ventilation compared to room air, Outcome 23 Hypopneas.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 3 NIV in overnight ventilation compared to room air
Outcome: 23 Hypopneas
Study or subgroup log [Relative rate] Relative rate Relative rate
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Single night
Milross 2001 -4.0197 (0.5052) 0.02 [ 0.01, 0.05 ]
0.005 0.1 1 10 200
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Analysis 4.1. Comparison 4 NIV versus no NIV during exercise testing, Outcome 1 6 minute walk test.
Review: Non-invasive ventilation for cystic fibrosis
Comparison: 4 NIV versus no NIV during exercise testing
Outcome: 1 6 minute walk test
Study or subgroup NIV No NIV
Mean
Difference
Mean
Difference
N Mean(SD)[metres] N Mean(SD)[metres] IV,Fixed,95% CI IV,Fixed,95% CI
1 Up to 1 week
Lima 2014 13 415.38 (77.52) 13 386.92 (84.89) 28.46 [ -34.03, 90.95 ]
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A D D I T I O N A L T A B L E S
Table 1. List of abbreviations
Abbreviation Definition Explanation
6MWT six minute walk test
ABG analysis of arterial blood gases
ACBT active cycle of breathing technique
AHI apnoea/hypopnoea Index
CF cystic fibrosis
COPD chronic obstructive pulmonary disease
CPAP continuous positive airway pressure a system that maintains a positive pressure in the circuitry
and airways throughout inspiration and expiration
CPT chest physiotherapy
CSS chest symptom score a validated CF quality of life measurement on a scale of
0 (worst) to 100 (best)
ESS Epworth sleepiness scale a scale measuring sleepiness ranging from 0 (best) to 24
(worst)
FEF25−75 flow rate between 25% and 75% of maximal expiration
FEV forced expiratory volume in 1 second
FRC functional residual capacity resting volume of the lungs
FVC forced vital capacity total volume of air expired during a forced expiration
following a full inspiration
Global PSQI Global score Pittsburgh sleep quality index sleep quality scale ranging from 0 (best) to 21 (worst)
LCI lung clearance index measured by multiple breath washouts; a sensitive mea-
sure of ventilation inhomogeneity
MEF50 maximal expiratory flow with 50% of vital capacity re-
maining in the lung
mmHg millimetres of mercury
mSpO2 mean oxygen saturation
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Table 1. List of abbreviations (Continued)
MSWT modified shuttle walk test incremental exercise tolerance test with minimum clini-
cally important difference = 40 m
nadirSpO the largest fall expressed in the absolute value of SpO
NIPPV non-invasive positive pressure ventilation
NIV non-invasive ventilation
NREM non-rapid eye movement a phase during sleep
ODI oxygen desaturation index
OEP optoelectronic plethysmography
PaCO partial pressure of carbon dioxide in arterial blood
PaO partial pressure of oxygen in arterial blood
PEP positive expiratory pressure an airway clearance technique
PSV pressure support ventilation
QoL quality of life
RCT randomised controlled trial
RDI respiratory disturbance index
RE respiratory exacerbations
REM rapid eye movement a phase during sleep
RR respiratory rate
SaO saturation of haemoglobin with oxygen in arterial blood
SD standard deviation
SOB shortness of breath
SpO2 saturation of haemoglobin with oxygen using pulse
oximetry
*SpO2 max the largest fall expressed as the difference with the SpO2
just before the manoeuvre
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Table 1. List of abbreviations (Continued)
*SpO mean the mean of *SpO max during the whole chest physio-
therapy period
SWT shuttle walk test
TcCO transcutaneous carbon dioxide
TDI transitional dyspnoea index a measurement of CF quality of life, scores ranging from
-9 (worst) to +9 (best); the minimal clinically important
difference is 1 unit
TLC total lung capacity total volume of air in lungs following a maximum inspi-
ration
TST total sleep time
TWT treadmill walking test
VI minute ventilation
VT tidal volume volume air inspired or expired during normal breathing
IPAP inspiratory positive airway pressure
PImax inspiratory respiratory muscle strength
PEmax expiratory respiratory muscle strength
Vab abdominal volume of the chest wall variable calculated from OEP
Vrca abdominal rib cage volume variable calculated from OEP
Vrcp pulmonary rib cage volume variable calculated from OEP
WH A T ’ S N E W
Date Event Description
13 February 2017 New search has been performed A search of the Cystic Fibrosis and Genetic Disorders
Review Group’s Cystic Fibrosis Trials Register and ad-
ditional searches by the authors identified a total of 11
new references to eight trials which were potentially el-
igible for inclusion
Two were additional references to two already included
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(Continued)
trials (Fauroux 1999; Holland 2003). Three new tri-
als (five references) have been included in the updated
review (Dwyer 2015; Lima 2014; Rodriguez Hortal
2016). One trial (single reference) has been excluded
(Fauroux 2000b). The remaining trial is still only re-
ported in abstract form and, due to having very limited
data, is listed as ’Awaiting Classification’ until further
data are available (Petrone 2009).
13 February 2017 New citation required but conclusions have not
changed
As we have only been able to include a limited amount
of new information in this version of the review, our
conclusions remain the same
H I S T O R Y
Date Event Description
24 March 2014 Amended Contact details updated.
14 March 2013 New search has been performed A search of the Cochrane Cystic Fibrosis & Genetic
DisordersGroup’s Cystic Fibrosis register did not iden-
tify any new references eligible for inclusion in this
review
14 March 2013 New citation required but conclusions have not
changed
No new references were included in this update of the
review, hence the conclusions remain the same
22 May 2012 Amended Contact details updated.
29 March 2011 New search has been performed A search of the Group’s Cystic Fibrosis Trials Regis-
ter identified three new references which were poten-
tially eligible for this review. One of these was an ad-
ditional reference to an already included study (Young
2008). Two references were excluded (Fauroux 2000a;
Riethmueller 2006).
26 April 2010 Amended Contact details updated.
30 September 2008 New citation required but conclusions have not
changed
Ashley Jones has stepped down as co-author.
12 June 2008 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
identified that the previously included 2006 abstract
has now been published as a full paper (Young 2008).
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12 June 2008 Amended Converted to new review format.
18 February 2008 Amended There have been some corrections to the graph labels
in the following graphs: 01 01, 01 02, 01 09, 01 10,
01 11, 01 12, 02 04, 03 07
22 August 2007 New search has been performed The sleep data from the Milross trial, which appeared
in the graphs removed in the previous update of the
review, have now been more appropriately analysed
using GIV methodology and are presented in this up-
date
A new search identified seven new references to six
studies. One of these references was to an already in-
cluded study (Holland 2003). Of the remaining six
references to five studies, three have not been included
as they were not randomised controlled trials in which
a form of pressure preset or volume preset NIV versus
no NIV was used in people with acute or chronic res-
piratory failure in CF and they have been added to the
excluded studies section (Falk 2006; Fauroux 2004;
Greenough 2004). Two studies were included as they
fulfilled inclusion criteria (Placidi 2006; Young 2006)
22 August 2007 New citation required and conclusions have changed Substantive amendment
23 May 2004 New search has been performed Amanda Piper and joined the review team as a second
co-author
A new search identified four new references. One trial
(Holland 2003) has been included and three trials have
been excluded (Fauroux 2001; Serra 2000; Serra 2002)
C O N T R I B U T I O N S O F A U T H O R S
The title for the protocol was conceived by the Cochrane Cystic Fibrosis and Genetic Disorders Group.
Both F. Moran and J. Bradley designed and assisted in writing the protocol and the review.
A. Piper has reviewed and contributed to the updated versions of the review.
F. Moran acts as guarantor of the review.
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D E C L A R A T I O N S O F I N T E R E S T
Amanda Piper was a clinical consultant to ResMed Australia until 2004. She has also been involved in: educational activities sponsored
by manufacturers of bilevel devices (Mayo Healthcare, Australia; Weinmann, Germany; Air Liquide, Australia; ResMed, Australia;
Philps Respironics, Australia) and transcutaneous carbon dioxide devices (Sentec, Switzwerland; industry-sponsored research (ResMed,
Australia) and has received equipment for research projects from distributors of bilevel equipment (Air Liquide, Australia; Mayo
Healthcare, Australia) as well as a competitive research grant from the ResMed Foundation.
Fidelma Moran and Judy Bradley received a NIPPY3 ventilator for a research clinical trial from Respicare.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In a post hoc change we have defined short-term trials as those with a duration less than three months. We decided to analyse single-
night interventions separately from other short-term trials as we did not feel it appropriate to combine them with other longer trials.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Sputum; Cystic Fibrosis [∗therapy]; Masks; Noninvasive Ventilation [∗methods]; Randomized Controlled Trials as Topic; Respiratory
Insufficiency [prevention & control]
MeSH check words
Humans
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